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Abstract
Background
Patients with increased levels of autoantibodies often have associated 
inflammatory disease. Immune complexes are often seen in inflammatory disease.
They may be formed by antibodies produced against the C lq  molecule which has 
been altered by the inflammatory process, and also by antibodies produced against 
C reactive protein (CRP) plasma levels of which become greatly increased during 
inflammation. These immune complexes can induce complement consumption, 
resulting in low serum levels of complement components, leading to pathogenesis of 
chronic inflammation and inflammatory disease. Raised levels of C3d are an indicator 
of increased complement consumption. It is not known whether antibodies to C lq  
and/or antibodies to CRP are responsible for autoimmune inflammatory disease or 
whether they are produced as a result o f the disease.
Aims
The aim of this thesis is to establish a link between levels of antibodies to Clq, 
antibodies to CRP, and inflammatory disease and thus provide evidence that these 
antibodies may be involved in the pathogenesis of chronic inflammation leading to 
inflammatory disease. This thesis tries to determine if (a) patients with inflammatory 
disease have a significantly different than normal level of antibodies to C lq, and of 
antibodies to CRP, and whether this depends on immunoglobulin isotype and type of 
inflammatory disease. Also investigated was (b) possible associations of antibodies to 
C lq, and/or antibodies to CRP with age and biological markers of autoimmune 
inflammatory disease. Another aim was (c) to determine if  there were increased levels
of C3d, an indicator of complement consumption, thus providing indirect evidence of 
the presence of immune complexes in patients with inflammatory disease.
Subjects and Methods
Patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) 
and heterogenous autoimmune inflammatory disease (HAID) were tested for 
antibodies to C lq, antibodies to CRP, C lq  levels and antibodies to double stranded 
DNA using enzyme-linked immunosorbent assay (ELISA) methods. Complement C3, 
C4 and C l inhibitor levels were measured by nephelometry and antinuclear antibodies 
(ANA) by immunofluorence techniques. An ELISA method was developed to 
measure C3d levels in patients with SLE, renal disease and HAID.
Results
It was demonstrated that differences in antibody titres to C lq  depend on the 
type of inflammatory disease and immunoglobulin isotype, and there is an association 
between antibody titres to C lq  (of IgG, IgA and IgM isotype) and age and various 
biological markers of disease activity. Inflammatory disease appears to affect the 
complement levels of C3, C4 and Cl inhibitor. There is a direct link between 
increased antibody titres to CRP and inflammatory disease and IgG antibodies to CRP 
increase as C3 and C4 levels decrease. Also, patients with inflammatory disease have 
increased levels of C3d.
Conclusions
The results show there is strong evidence that antibodies to C lq  and antibodies 
to CRP of certain immunoglobulin isotype (IgG, IgA and IgM) form immune 
complexes which induce complement consumption. The resulting complement 
deficiency would impair the ability of complement to clear immune complexes. An 
autoimmune response is then triggered and so the cycle goes on leading to chronic 
inflammation and inflammatory disease. Future studies should try to determine how 
and why this inflammatory cycle is initiated. Certainly, it appears that measurement of 
antibodies to CRP and possibly antibodies to C lq  may prove to be a useful tool for 
diagnosing inflammatory disease.
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Abbreviations
CRP C-reactive protein
EDTA ethylenediaminetetra-acetic acid
EGTA ethylene glycol-bis(a-aminoethyl ether) N,N,N’,N’-tetraacetic acid
ELISA enzyme-linked immunosorbant assay
GBM glomerular basement membrane
HAID heterogenous autoimmune inflammatory disease
HUVS hypocomplementaemic urticarial vasculitis syndrome
MASP MBP-associated serine protease
MBP mannan-binding protein
MPGN membranoproliferative glomerulonephritis
RA rheumatoid arthritis
SLE systemic lupus erythematosus
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Glossary
Antibody Protein with the moleclular properties of an immunoglobulin, produced 
by plasma cells, in response to stimulation by antigen and capable of 
specific combination with antigen
Antigen A substance that activates lymphocytes by interacting with the 
combining sites of T- or B-cell receptors
Autoantibody Antibody capable of specific reaction with an antigen that is a 
normal constituent of the body of the individual by which that 
antibody was formed
Clq A subcomponent of the first component (C l) o f the classical pathway which, 
after binding to the Fc regions of immunoglobulins induces activation of the 
cascade of proteins composing the classical pathway
C 3 d  A fragment produced following the breakdown of complement as a result of 
the activation of the classical and/or alternate pathways
Complement An enzymatic system o f serum proteins that is activated by 
many antigen-antibody reactions and which is essential for
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antibody mediated immune haemolysis and bacteriolysis and 
plays an important part in several other biological reactions
C R P C Reactive protein : an acute phase beta-globulin which reacts with C-
substance, a polysacharride derived from pneumococcus, in the 
presence of calcium ions
Dialysis The use of semipermeable membranes to separate substances of
differing molecular weights in solution
Fc fragment Consists of the C terminal half of the two heavy chains linked by 
disulphide bonds. No activity as an antibody but carries sites for 
fixation o f complement
Glomerulonephritis A term applied to a group of kidney diseases, in all o f
which the major lesion is in the glomeruli
Heavy chain A polypeptide chain present in all immunoglobulin molecules.
Each chain is linked,usually by disulphide bonds to a light 
chain and to another identical heavy chain
Hypocomplementaemia Any condition in which serum complement levels are
low
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IgG The major immunoglobulin in the serum o f humans, the molecular
weight of which is 150 000 = 7S. It fixes complement and crosses 
human placenta
IgA The major immuoglobulin of the external secretions, but also present
in serum and has many antibody activities
Ig M  High molecular weight (19S) immunoglobulin which is a cyclic
pentamer of five basic units o f heavy and light chains linked by 
disulphide bonds. There is also a monomeric form (7-8 S). It has a high 
carbohydrate content and fixes complement
Im m u n e complex A macromolecuiar complex of antigen and antibody molecules-
bound specifically together. May be present in soluble form 
especially in antigen excess or as a precipitate
Immmio deficiency Any condition in which a deficiency o f humoral or cell-
mediated immunity exists
Immimo globulins Member of a family of proteins each made up o f light
chains and heavy chains, linked together. All antibodies are 
immuno globulins
Ochterlony test Double diffusion precipitin test in which wells are cut in
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an agar plate and filled with appropriate solutions of antigen 
and antibody which then diffuse through the agar gel to meet to 
form lines of precipitate
7S antibody Immunoglobulin molecules with sedimentation coefficient of about 
7S used as a synonym for IgG
Sjogrens disease Chronic inflammatory disease of lacrimal and salivary 
glands often with conjunctivitis and rheumatoid arthritis
Systemic Lupus Erythematosus Disease causing widespread degeneration of
connective tissue and lesions
Urticaria Skin rash characterised by localised, increased erythematosus, itchy 
weals due to histamine and vasoactive substances
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Chapter 1
1 Introduction
1.1 The complement system
The complement system is an important humoral system which 
mediates many activities that contribute to inflammation and host defence (1).
It consists of a group o f individual proteins that are activated in the form 
of enzyme cascades. It non-specifically complements the specific effect of 
antibody in the opsonisation and lysis of micro-organisms. Four of the 
functions the complement system performs are ;
1. cell activation : i.e. activation of neutrophils
2. opsonisation - rendering cells vulnerable to phagocytosis by the adherence 
of opsonins
3. cytolysis : i.e. the breakdown and destruction o f foreign cells and 
bacteria (2)
4. prevention o f immune precipitation : the conservation of immune 
complexes in soluble state to ensure their clearance fi'om the circulation 
by the mononuclear phagocytic system.
1.1.1 Complement pathways
The complement system can be activated by one o f three enzyme 
cascade pathways. The most studied are the classical pathway and the 
alternative pathway, but all end in the cleavage of C3, the central event in the
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complement system (3). These pathways can play an important role in the pre- 
immune phase as well as amplifying the humoral and cellular immune 
response. The pathway components are shown in Table 1.1.1.
Most components are IS globulins and consist mainly of one or two 
peptide chains joined by disulphide bonds. The main exceptions are C lq  with 
its unique structure and C4 with three peptide chains and the collectin 
MBP (1).
1.1.2 The Classical pathway
To initiate classical pathway activation the antigen bound antibody 
on the cell surface or in an immune complex interacts with the first 
component of the classical pathway, C l. As the components were numbered in 
the order o f their discovery, the activation sequence is C W  C4 C2 C3 
C5 through to C9 (Figure 1.1.2). The classical pathway evolved to take 
advantage of the specificity of antibodies in identifying targets for activation, 
to provide an effector mechanism for antibody - mediated functions. Antigen 
-antibody complexes are the most common classical pathway activators, but 
there are others such as the MBP pathway (described later in 1.1.5).
The Cl component is a multimeric complex which consists of the C lq 
protein and C lr 2 C ls 2 tetramer, the integrity of which is Ca^^ dependant. The 
C lq  protein is the recognition subunit that can interact with the 
immunoglobulin molecule. The intact C l complex is required for activation, 
so the process can prevented by dissociation of C lqrs when the calcium is 
removed. Thus, the anticoagulant compounds EDTA, EGTA, citrate, and 
oxalate that work by chelating calcium are also anti-complementary 
compounds. EDTA also prevents activation of the alternative pathway because
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it chelates magnesium, required for both the classical pathway and alternative 
pathway C3 convertases (2,3).
There are several steps involved in the activation of C l leading to the 
formation of the C l esterase C l s. Binding of Cl to immune complexes via 
Clq, the recognition unit o f C l, induces a conformational change that occurs 
within the C lq  molecule. This change favours spontaneous activation of C lr 
which, once activated, enzymatically cleaves a peptide bond in the second C lr 
monomer. The two enzymatically active monomers then cleave the two C ls 
molecules which activates them. This process is called "autocatalytic 
activation" of C lr and can occur in serum even in the absence of activators 
of C l (1). The sequential binding of C lr and C ls generates Cl esterase 
enzyme activity for the cleavage and activation of C4 and C2. Both molecules 
are cleaved to produce a and b binding fragments. The complex C4bC2aC2b is 
termed the classical pathway C3 convertase which cleaves C3 into two 
fragments, C3a which possesses anaphylatoxins and chemotaxins activity and 
C3b which binds to the initiating complex and promotes many of the 
biological properties of complement. The C5 convertase generated initiates the 
final lytic pathway.
1.1.3 The Alternative activation pathway
The alternative pathway is relatively inefficient in the tissues in 
comparison to the classical pathway as high concentrations of the various 
components are needed. However, C3 convertase is generated without the 
need for antibody. C l, C4 or C2 because the activators are bacterial cell walls 
and endotoxin. The initial cleavage of C3 in the alternative pathway happens
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continuously and independently generating a low level o f C3b. C3b is an 
unstable substance, which becomes inactive if a suitable acceptor surface is 
not found. When a suitable acceptor surface is found, C3b is able to use 
factors D and B of the alternative pathway to produce the active enzyme 
C3bBb which can break down more C3, providing still more C3b. This is 
known as the "positive feedback loop" of the alternative pathway. In the 
presence of properdin CSbBb is stabilised in the presence o f properdin to form 
the C5 convertase o f the alternative pathway (2,4).
1.1.4 The Lytic pathway
The final lytic pathway of complement in both the classical pathway 
and alternative pathway involves the sequential attachment of the components 
C5, C6, C7, C8 and C9 and results in lysis of the target cell.
The component C5 is cleaved into C5a and C5b fragments. The C5b 
fragment remains bound to the C5 convertase and acts as an acceptor for the 
C6 component, which in turn binds C7. This binding causes a conformational 
change in C7 which allows it to attach to the lipid bilayer o f the plasma 
membrane through which holes are punctured. The C5b67 complex then in 
turn causes a change in C8 also allowing it to attach to the lipid bilayer. 
Multiple units of the C9 component and the assembly o f the membrane attack 
complex then enlarge the punctures. Proteins, nucleic acids and high 
molecular-mass substances leave through these punctures and the cell 
becomes lysed and dies (5).
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1.1.5 The MBP pathway -  the Collectins
Lectins are carbohydrate-binding proteins other than antibodies and 
enzymes (11). Collectins are a family of C-type (Ca^^ dependant) lectins with 
collagenous regions. There are five such lectins: lung surfactant protein A and 
D ( SP-A and SP-D), conglutinin, mannan-binding protein (MBP), and CL-43. 
They are composed of trimeric subunits containing a collagenous section and a 
C-terminal globular carbohydrate-recognising domain containing the 14 
invariant amino acids characteristic of the C-type lectins. Complete molecules 
MBP and SP-A molecules are composed of up to six such subunits, while 
conglutinin, SP-D and CL-43 contain up to four subunits.
The collectins bind to carbohydrates on yeast, bacteria and viruses.
To be of biological use, humoral lectin should also possess structures with 
biological effector functions. MBP has been demonstrated to be capable of 
complement-mediated lysis of mannan-coated erythrocytes, which is C4 
dependant (7), and killing bacteria (8). Also, when MBP binds to zymosan, a 
cell wall preparation of baker’s yeast, it activates the ClrzClso complex 
without the involvement of C lq (9) and MBP activates C4 and C2 through the 
action of a new Cls-related serine protease called MASP (MBP-associated 
serine protease) (10). As in the C lq  molecule, the MBP molecule has 
tetramers of subunits which contain N-terminal collagen-like helixes and a C- 
terminal globular recognition domain. The MASP molecule dimerizes like C lr 
and C ls and also shares 40% of their amino acid residues. The structures of
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these two proteins show MBP to be homologous to C lq  and MASP to 
ClrzClsz.
Obsevations on the opsonising capacity of human serum indicate that 
the lectin pathway is o f major importance and was directly correlated to the 
concentration o f MBP in indivdual sera. (11).
Another likely biological effector function of the collectins is 
associated with the observation that these molecules interact the C lq  receptor 
(now called the collectin receptor )(12). MBP, SP-A and conglutinin inhibit 
the binding of radiodinated C lq  to purified, solid-phase collectin receptor and 
to myeloid cell line U937, and radioiodinated collectin receptor binds to the 
above collectins coated onto plastic. The collagenous section reacts with the 
collectin receptor found on many cells including phagocytes.
The available structural and functional information on the collectins 
indicate that this family of lectins plays a significant role in the innate 
antimicrobial defence (13).
1.1.6 Clinical relevence associated with the complement system
The inherited deficiency of C l esterase inhibitor can produce an 
uncontrolled activation of the early components of the complement system 
which causes angioedema in the skin, the gastrointestinal and genitourinary 
tracts and the larynx (14). C2 deficiency is the commonest one associated with 
lupus. Lupus-like syndromes of malar flush, arthralgia, glomerulonephritis, 
fever or chronic vasculitis have been associated with patients who have 
inherited C l, C3 or C4 deficiency. This deficiency usually compromises the 
ability to combat viral antigens and leads to immune complex diseases.
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Individuals with C3 deficiency are more likely to suffer from life threatening 
infections such as pneumonia, septicaemia and meningitis while those with 
deficiencies o f C5, C6, C7 or C8 have presented with gonococcal infection 
(15).
Diseases such as systemic lupus erythematosus, which consume the 
complement system via the classical or alternate pathways, can impair 
complement activity, which increases susceptibility to infection. The 
consumption o f the early classical pathway components reduces their capacity 
to neutralise or lyse certain viruses.
1.2 The Complement Component C lq
1.2.1 Structure of complement component C lq
C lq  is a serum protein o f molecular weight 410 kDa (16). It is a large, 
highly cationic glycoprotein. Electron microscopy shows the C lq  molecule 
is a large complex hexametric structure (fig. 1.2.1) which has been shown to 
consist of 18 polypeptide chains of three kinds, six A chains, six B chains 
and six C chains (17,18). The three types differ in amino acid sequence but 
are similar in overall organisation ; a short, N - terminal segment containing a 
cysteine residue followed by a collagen-like, Gly-Xaa-Yaa repeating sequence 
and then by a C-terminal, non-collagen-like sequence. Disulphide bond 
linkages, between A- B and C-C chains, in the N-terminal segments of the 
chains and the formation of triple helices between the collagen-like regions of 
each o f the A-, B- and C chains, results in the assembly o f the eighteen
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polypeptide chains into an overall ‘ bunch of tulip-like’ structure. The 
insertion of a threonine residue interupts the middle of the collagen-like region 
of the A-chain between the 10th and the 11th Gly-Xaa-Yaa repeating triplets. 
The C-chain is interupted by the insertion of three resiciues , Ala-Ile-Pro, 
between the 11th and 12th Gly-Xaa-Yaa repeats. These interruptions in the A- 
and C- chains disrupt the triple-helix at its mid-point causing the C-terminal 
portions o f the collagen-like stalks of C lq  to diverge away from the axis of the 
rest of the molecule i.e. ‘bending the stalks’ (19,20,21).
The hexameric globular region represents the recognition site of C lq  to 
acceptor molecules : a variety of substances have binding site(s) for C lq  or 
interact directly with the cationic C lq  molecule resulting in activation of Cl 
and the classical pathway of complement.
Substances and cells that which interact directly with C lq  include :
- Immunoglobulins e.g. Fc portion IgM, IgG ( IgG3, IgG l, IgG2 )
- Serum proteins e.g. C-reactive protein (CRP), Clrz - ClS] complex, 
frbronectin
- Polyanions e.g. PO4 ,S04
- Viruses e.g. envelope of certain RNA viruses, Moloney viruses, HTV-l
- C lq  receptors on ; B-cells, PMNs, monocytes, fibroblasts, endothelial cells, 
platelets
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1.2.2 Genomic structure o f C lq
The A-, B- and C chains of human C lq have been characterised at the 
cDNA and genomic levels with the genes being approximately 2.6 kb, 2.5 kb 
and 3.2 kb long respectively each containing a single intron o f approximately
1.2 kb(22).The intron is located within the collagen-like region coding 
sequence in the A- and C- chain genes and immediately precedes the sections 
coding for the interruption in the repetitive nature of the Gly-Xaa-Yaa 
repeating sequences in these chains. The A-, B- and C- chain genes are 
arranged 5’ to 3 ’ in twos ordered at A-B-C within the region lp34. Ip36.3 on 
a 24 kb DNA stretch on chromosome 1.
1.2.3 Binding of C lq  to immunoglobulins
The interaction between Cl and immunoglobulins takes place between 
the C lq  globular domains and the Cy2 domain of IgG or the Cp3 domain of 
IgM. This was shown by experiments in which the globular domains were 
shown to inhibit the reaction between immune complex and C l after the 
stalks were removed by collagenase digestion (23). Studies of the effect of 
ionic strength on thermodynamics of the interaction suggest a stronger bond is 
formed between C lq  and IgG than C lq and IgM due to three salt bridges
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being foimed as each C lq globular domain is bound in the case o f IgG 
whereas only two are formed in the case of IgM (24,25).
1.2.4 Interaction of C lq  with IgG (Figure 1.2.4)
In order to activate the complement process, the shape o f the C lq  
molecule must be distorted in à certain way in a process that depends on the 
attachment of the C lq  heads to at least two Fc sites. The C lq  molecule is not 
flexible enough to bind to the two sites on an IgG molecule simultaneously, 
therefore bivalent binding is only achieved when C lq  spans two IgG 
molecules. The two IgG molecules must be within 40nm for a 
single C lq  molecule to bridge them because this is the maximal armspan o f 
Clq. The distances between neighbouring IgG molecules depends on the 
density of the bound immunoglobulins, on an antibody- coated c e l l . For 
example, on an erythrocyte with 1000 molecules of bound IgG, only 1% of the 
molecules are close enough to be spanned by C lq  with 20 000 molecules, 20% 
of the molecules can be spanned (3).
1.2.5 Interaction of C lq  with IgM
A pentameric IgM molecule has at least three binding sites for C lq and 
their spatial distribution allows a single C lq  molecule to bind to a single IgM 
molecule firmly enough to be activated. However, the IgM binding sites are 
normally hidden and only become exposed when the IgM molecule binds to 
antigen and adopts a staple-shaped configuration (126).
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1.2.6 Immune complex clearance
Clearance of immune complexes occurs by activation o f the 
complement system. The classical pathway of the complement system may be 
activated by IgM and IgG containing immune complexes after binding to the 
globular head portions of C lq (26). Binding of Fc regions of immunoglobulins 
to the globular head portions of C lq  induces conformational changes of the 
the collagen-like region, which alters the dynamic equilibrium between C lq 
and the other subcomponents of C l (4,27). This results in the activation of the 
classical pathway which then results in the conservation of immune complexes 
in soluble state and ensures their clearance from the circulation by the 
mononuclear phagocytic system (4).
1.2.7 Clinical relevence associated with Cl complex
The C l macromolecule is derived from five independently regulated 
genes and the catabolism of Cl is complex. The C lq  component is generated 
from 18 polypeptides, each of which must undergo extensive postsynthetic 
modification to permit assembly. The association of C ls and C lr 
subcomponents with C lq is constrained by primary and higher order structure 
(the stringency of which is not yet known). Considering these complicated 
mechanisms involved in normal C l metabolism, the relative infrequency of 
genetic deficiencies of Cl is surprising (28).
There are four C l deficiency syndromes subgroups:
Type I : no C lq  is detected in serum using conventional methods for protein
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Type n  ; a dysfunctional C lq  protein is present in normal or reduced amounts 
Type in  : an inherited deficiency of C lr (with associated decrease in steady 
state C ls serum levels).
Type IV : a hypercatabolic form of C l deficiency
The hypercatabolic form of C l deficiency was the first to be noted in which 
studies showed that decreased C lq  was associated with several 
immunoglobulin deficiencies but that the levels were lowest in patients with 
severe combined immunodeficiency (SCID) (29,30), and that bone marrow 
transplantation restored C lq  levels to normal (31). The basis of these 
observations was revealed in a study which demonstrated hyper catabolism of 
C lq  in association with hypogammaglobulinemia (32). However, the C lq 
deficiency in SCID is o f minor importance because the extreme deficit in 
cellular and humoral immunity accounts for the devastating clinical 
manifestations of the disorder.
Although most C lq  deficient patients develop symptoms in early 
childhood some do not develop until adulthood. The symptoms can be 
prominent ;
- cutaneous manfestations of systemic and discoid lupus erythromatosis
- renal disease
- arthritis and arthralgias
- cold intolerance or Raynaud phenomenon
- mucosa lesions (often stomatitis ) (28)
Antinuclear antibodies, anti-Sm and circulating immune complexes are 
frequently found in patients serum and more rarely, anti-Ro antibodies. Skin 
and renal biopsies in several patients may also have symptoms fairly typical
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for the renal and/or systemic collagen vascular disease manifested. C l inhibitor 
and C ls serum levels are elevated which emphasises the independent 
regulation of C lq , C lr  and C ls synthesis and catabolism.
It has been suggested that C lq  deficiency is also associated with 
increased susceptibility to infections (34) though it is' difficult to be certain 
because some SLE patients, without primary complement deficiency, have 
increased susceptibility. Also, some C lq deficients have no symptoms, 
reflecting the importance of other genetic or environmental factors necessary 
for expression o f disease.
1.2.8 Function and disease characteristics of antibodies to C lq
After the binding to an immune complex, the physiological role of C lq 
may be influenced by antibodies to Clq. Decreased Cl activation by binding 
of antibodies to C lq  to the collagen-like region of C lq  could functionally 
resemble a C lq  deficient state and result in immune complex precipitation in 
the tissues. Alternatively, antibodies to C lq  may also stimulate C l activation 
after binding to C lq . The association between antibody titres to C lq  and 
hypocomplementaemia may result fi*om such stimulation (35) although studies 
on activation o f the classical pathway in the presence o f antibodies to C lq 
could not demonstrate any effect so, at present, there is no evidence to support 
the possibility that antibodies to C lq  directly influence C l activation (36).
Combined data suggests that antibodies to C lq  may exert a 
pathogenetic role by contributing to immune complex deposition or formation 
in glomeruli which results in inflammation (37).
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Various studies have suggested that the occurrence of antibodies to 
C lq  may have no pathological or diagnostic significance (38,39). However, 
the occurrence of antibodies to C lq  may be associated with specific diseases 
and the serial measurement of antibody titres to C lq may provide an objective 
tool for patient management. The first cross- sectional study on associations 
between antibody titres to C lq  and clinical variables of disease activity in SLE 
patients demonstrated that the highest antibody titres to C lq  were found in 
patients with active lupus nephritis (35). Subsequent studies demonstrated that 
rises in antibody titres to C lq have predictive value for ensuing relapses of 
lupus nephritis, and a comparison between titres of anti-dsDNA antibodies and 
antibodies to C lq  suggested both equally effective in predicting renal relapses 
of SLE (41,42).
Immune complexes may be formed either in the circulation or locally 
in tissues. C lq  molecules which are part of an immune complex, are potential 
antigens for antibodies to Clq. Thus, the formation and size of immune 
complexes may be increased by antibodies to Clq. The induction of the lattice 
formation of immune complexes can lead to inflammatory reactions such as 
the development of glomerulonephritis (43).
Antibodies to C lq  may also bind to C lq  that has already deposited in 
tissues leading to in situ immune complex formation which is considered to 
play an important role in the pathogenesis of glomerulonephritides, The 
preferential binding of antigens on the glomerular basement membrane (GBM) 
may play a role in this type of immune complex formation (44).
Evidence for the involvement of antibodies to C lq  in disease include 
the findings that large C lq  containing circulating immune complexes have
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been associated with lupus nephritis (44,45) and with rheumatoid vasculitis 
(46). Studies of renal biopsies o f lupus patients invariably demonstrate the 
presence of immunoglobulins and C lq  in (40) glomeruli and significant 
increases o f antibody titres to C lq  preceding the development of lupus 
nephritis lends further support to a pathogenetic role of antibodies to C lq  in 
the development of nephritis. Antibodies against the collagen-like region of 
C lq  were recovered from glomeruli of 80% of SLE patients suffering from 
diffuse proliferative lupus nephritis.
Systemic lupus erythematosus (SLE) is considered the prototype of an 
immune complex disease in humans. Immune complexes that can be detected 
in both the tissues and circulation increase in numbers as autoantibody 
production increases. Each step in the clearance of immune complexes, 
including activation of the complement system, binding to complement 
receptors for transportation and the degradation o f immune complexes, may be 
disturbed in SLE patients.
Because the classical pathway of the complement system 
prevents precipitation o f immune complexes, patients with deficiencies of 
components o f the classical pathway of the system may develop SLE-like 
syndromes suggesting that changes in the interaction between immune 
complexes and complement lead to SLE development (47,48,49). Activation 
of the classical pathway by binding of C lq  to an immune complex serves to 
maintain immune complex solubility by preventing aggregation. Therefore 
activation of the classical pathway by immune complexes depends on their 
interaction with C lq  and is a prerequisite for the prevention o f immune 
complex diseases.
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When antibodies to C lq  were reported to be present in the serum of 
SLE patients in 1984 (50), it was considered that antibodies to C lq  may not 
only participate in immune complex formation, but may also interfere with the 
physiological immune complex clearance by interaction of antibodies to C lq 
with Clq. Thus, antibodies to C lq may play a pathogenetic role in immune 
complex diseases such as SLE.
A number o f assays have been employed to measure circulating 
immune complexes in order to relate titres of circulating immune complexes 
to the presence of disease manifestation (51). The most widely used is the 
solid phase C lq  binding assay, a radioimmunoassay based on the interaction 
between C lq  and immune complexes, where immune complexes bind to C lq 
which is fixed to polystyrene tubes (52). From this assay it was found that as 
well as immune complexes there were low molecular weight (7S) C lq  
precipitins which were present in high titres in SLE patients' serum, especially 
patients with lupus nephritis (53,54,55,56,57).
Proof for the antibody nature of “7S C lq  precipitins” was supplied in 
1984 (50). Monomeric IgG was demonstrated to bind to C lq  through its 
antigen binding rather than its complement binding region. Procedures known 
to destroy the ability of IgG to bind to C lq like exposure to low pH, reduction 
and alkalation, did not influence the binding of IgG to C lq  in the serum of 
SLE patients (50). Therefore CH2 binding of IgG to C lq  was not responsible 
for the binding of 7S IgG to C lq . The epitope against which antibodies to 
C lq  were directed was found to be located on the collagen like region of Clq. 
(58,59). Also the binding of IgG antibodies to C lq  was of high affinity
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directed against C lq  bound to a solid phase and not affected by the fluid phase 
C lq  (60).
In recent years evidence was provided for the presence of IgG 
antibodies to C lq  in a number of autoimmune and renal diseases (Table 1.2.8). 
As well as SLE, IgG antibodies to C lq  were found to’’be present in patients 
with hypocomplementaemic . urticarial vasculitis syndrome (HUVS), 
membranoproliferative glomerulonephritis (MPGN), rheumatoid arthritis and 
systemic sclerosis (61,62,63). The occurrence of antibodies to C lq  as a natural 
antibody in the general population was also investigated and it was found that 
the occurrence of IgG antibodies to C lq  increased at an older age (64).
1.3 C-Reactive Protein and antibodies to C-Reactive Protein
The serum concentration of a number of proteins, such as an increase 
in the alpha and beta globulins, change rapidly during infection and illness. 
These are called acute phase proteins and their concentration can increase up 
to 1000 times their normal levels and they remain elevated throughout the 
infection (65,66). An example of an acute phase beta-globulin is C Reactive 
Protein, so-called because in the presence of Ca^ "^  ions. It reacts and 
precipitates with C-substance, a polysaccharide derived from pneumococcus, 
which is how it was first discovered (67).
The origin and function of CRP are obscure, but its increased presence in 
blood serum indicates that an inflammatory reaction is going on somewhere in 
the body and its estimation is particularly valuable as an objective and 
quantitative measure of illness in e.g. clinical trials.
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CRP is a molecule o f distinctive pentameric structure (Figurel.3) which 
binds avidly to DNA immune complexes from dead or damaged cells, after 
which it then activates the classical pathway via C l as efficiently as IgG 
antibodies. Therefore CRP can induce all the known inflammatory responses 
of the complement system. When CRP binds to ’ bacteria it promotes 
complement binding which facilitates the uptake of bacteria by phagocytes, 
known as opsonisation. Acute phase proteins are therefore important in the 
innate immunity to infection and CRP is likely to offer the most useful screen 
for inflammation in samples obtained from a wide range o f patients (68).
Antibodies to CRP have been used to show the presence of CRP in the 
brains of those suffering from Alzheimers disease (69) and have been reported 
in patients suffering from Toxic Shock Syndrome (TOS) (70). TOS resembles 
autoimmune diseases such as SLE or systemic scleroderma. Consuming 
adulterated olive oil caused the affected patients to develop symptoms 
resembling the above diseases therefore this project will try to ascertain if 
there is a correlation between levels of antibodies to CRP and inflammation.
1.4 The Complement Component C3d
The complement system plays an essential role in the body’s defence 
system against pathogenic organisms. The C3 component is the key 
component common to both the classical pathway and the alternate pathway. 
When activated via bacterial invasion, the C3 molecules break down into 
different fragments including C3d, the size of which is small enough to pass 
through the glomerular basement membrane and which can be detected in 
urine samples.
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Activation o f the complement cascade is of importance in the 
pathogenesis of immune damage in such disorders as rheumatoid arthritis and 
SLE. Measurement o f intact components such as C3 and C4 provides only 
limited information concerning complement activation. In rheumatoid 
arthritis, for example, levels of C3 may be normal or raised in the presence of 
complement consumption since C3 behaves as an acute-phase reactant (71). In 
certain diseases, such as SLE and childhood autoimmune chronic active 
hepatitis, low levels of C4 are observed and are often genetically 
determined by the possession of C4 null allelic variants (72,73). Therefore 
interest has focused on measurement of the products of complement 
breakdown in an attempt to investigate in vivo activation of both classical and 
common pathways. The classical pathway is activated by immune complexes 
and the alternate pathway by bacterial lipopolysaccharides. Both result in the 
enzymic cleavage of C3, generating C3d. Fixed C3 is the major mediator 
of the adherence functions of the complement system involving polymorphs, 
lymphocytes and macrophages (74). Bound C3b is also necessary for the 
terminal complement sequence to proceed. This generates C5a, an important 
chemotactic attractant, and leads to stable fixation of the lytic C5b-9 complex 
(75).
Following its initial activation to C3b, metabolism o f the C3 molecule 
proceeds, via the mediation of the C3b inactivator (I) and BlHglobulin (H), to 
cleave into the C3c and C3dg fragments (76). C3c is rapidly catabolised and 
cleared. In contrast, the turnover of C3d is relatively slow and as a result of its 
small molecular size (35 000-43 000 mol.wt), it can reach the plasma by 
diffusion from extravascular sites of complement activation (77). C3dg
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provides a binding site for complement receptor type 2 (CR2), which is a 
plasma-membrane structure involved in B-cell activation and proliferation.
Therefore measurement of the plasma concentration of C3d is a 
more useful index of in vivo complement activation in humans and also the 
ratio of its concentration to that of intact C3 reflects the relative kinetics of C3 
synthesis and catabolism. Renal disease in SLE is of variable severity with 
protean manifestations, ranging from asymptomatic proteinuria and 
haematuria to active nephritis to acute or chronic renal failure. The clinical 
management is complicated by the extreme clinical and pathological diversity 
in that patients with SLE can have a broad range of glomerular lesions 
including glomerulonephritis and intestinal nephritis (78). Many patients with 
lupus nephritis have very severe extrarenal systemic disease and may be 
acutely ill with high fevers and increased anti nDNA antibodies and low 
complement levels (79).
1.5 Aims of this project
Immune complexes can induce complement consumption 
resulting in low serum levels of complement components (80). Raised levels 
of C3d are an indicator of increased complement consumption. Immune 
complexes, which are often seen in inflammatory disease, may be formed by 
antibodies generated by the C lq  molecule, altered by the inflammatory 
process and, by antibodies generated by CRP levels, which become greatly 
increased by inflammation.
The aim o f this thesis is to establish a link between levels of antibodies 
to C lq, antibodies to CRP, and inflammatory disease and thus provide
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evidence that these antibodies may be involved in the pathogenesis of chronic
inflammation leading to inflammatory disease.
The following was carried out to try to achieve this aim :
• the development o f two quantitative methods, one to measure titres of 
antibodies to C lq, the other to measure titres of antibodies to CRP, of 
isotypes IgG, IgA and IgM in both cases
• determining if  patients with inflammatory disease have a significantly 
different than normal level of antibodies to C lq, and o f antibodies to CRP, 
and whether this depends on immunoglobulin isotype and type of 
inflammatory disease
• the investigation of whether there are associations of antibodies to C lq, and 
of antibodies to CRP with age and biological markers of autoimmune 
inflammatory disease
• the development of a quantitative method to measure complement 
component C3d
• determining if there were increased levels of C3d in patients with 
inflammatory disease compared to normal
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Chapter 2
2 Materials and methods
Complement C3, C4 and Cl inhibitor were all measured using 
nephelometry techniques. A Behring B N A 13 Nephelometer was employed.
, The Double Diffusion technique was used to confirm the purity of C lq 
and a spectrophotometer was employed to assess the concentration of purified 
Clq,
ELISA methods were used to quantitatively measure antibodies to 
C lq, C lq  levels, antibodies to CRP, anti ds-DNA antibodies and C3d levels. 
Antinuclear antibody titres were determined using immunofluorescence 
techniques.
2.1 The Patients
Blood sera from 97 patients from various hospitals in the West of 
Scotland area were involved in the experiments which comprised this thesis. 
The samples of blood sera were sent to the Department of Immunology, 
Western Infirmary, Glasgow for various immunological tests. A group of 64 
patients with inflammatory diseases, were subdivided into groups of disease 
categories ; 27 patients with systemic lupus erythematosus (SLE), 23 with 
rheumatoid arthritis (RA) and 14 with symptoms o f heterogenous autoimmune 
inflammatory diseases (3LAID) which included urticaria, 
hypocomplementaemic urticarial vasculitis syndrome (HUVS), joint pain, 
Sjogrens, Raynaulds, scleroderma, mixed connective tissue disease (MCTD)
41
and arthralgia. 76 of the patients were also divided into a group of 38 positive 
for antibodies to dsDNA and a group of 38 negative for antibodies to dsDNA. 
The sera from a total of 30 healthy laboratory personnel (normal healthy 
donors) were used as controls.
The EDTA-plasma of 45 patients from various hospitals in the west of 
Scotland area, 15 SLE, 15 renal disease and 15 HAJD, were used in the C3d 
experiments. The EDTA-plasma of 11 normal healthy donors were used as 
controls.
2.2 Definition and Clinical Criteria of SLE
SLE is defined as an inflammatory multisystem disease o f unknown 
etiology with diverse clinical and laboratory manifestations and a variable 
course and prognosis. Immunologic aberations give rise to excessive 
autoantibody production, some of which cause cytotoxic damage while others 
participate in immune complex formation resulting in inflammation.
The clinical manifestations may be constitutional or result from 
inflammation in various organ systems, i.e. skin and mucous membranes, 
joints, kidney, brain, serous membranes, lung and heart. These organ systems 
may be involved individually or in any combination. Vital organs such as 
kidneys and the brain affected by SLE account for significant mortality. 
Mortality can result from tissue damage due to the disease process or its 
therapy.
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Because of the various manifestations and variable courses of SLE, 
there is a need for classification criteria. The 1982 ACR criteria for the 
classification of SLE (127) .helps distinguish patients with SLE fi"om patients 
with other connective tissue diseases.
These criteria are : malar rash
discoid rash 
photosensitvity 
oral ulcers
haematologic disorder
arthritis
serositis
renal disorder
neurologic disorder
immunologic disorder e.g. anti ds DNA antibody 
positive
antinuclear antibody positive 
Patients who satisfy at least four of these criteria are said to have SLE.
2.3 Definition and Clinical Criteria of Rheumatoid Arthritis
RA is a common severe inflammatory disorder, which affects people 
of all ages, but especially young adults and premenopausal woman, and is 
characterised by immune driven, chronic inflammation. Patients follow a 
variable course, involving many exacerbations and remissions of disease 
activity and many cases are chronic and progressive, resulting in severe 
disability and sometimes death.
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Clinical features are that rheumatoid factors are detectable in the serum 
in most cases and the main target organ is the synovial lining o f joints, bursae 
and tendon sheaths. Synovitis results in erosion o f articular cartilage and 
marginal bone with subsequent joint destruction. Extra-articular features are 
common, numerous and sometimes serious. Most are due to serositis, nodule 
formation or vasculitis.
The Revised Diagnostic Criteria for the Classification of Rheumatoid 
Arthritis was set up in 1987 (128) and is listed as follows :
• morning stiffness for at least 1 hour every day for at least 6 weeks
• arthritis in at least three joints with swelling or fluid
• arthiitis of hand j oints
• symmetric joint swelling and involvement
• subcutaneous nodules
• radiographic changes typical of RA
• positive for rheumatoid factor test
Patients who satisfy at least four of these criteria are said to have RA.
2.4 Definition and Clinical Criteria of Renal Disease
Renal disease is mostly defined by the laboratory assessment of renal 
function and structure (81). The clinical features are :
• Renal Insufficiency and Renal Failure which is defined as a decrease in 
glomerular filtration rate and can be acute and chronic
• Nephritic and Nephrotic Syndrome : also known as nephritis, is defined as 
the total urinary protein excretion in excess of 3.5grams per day, reduced
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serum albumen concentration, elevated serum lipid concentration and 
oedema
Renal Tubular Syndromes, defined as disorders resulting fi-om abnormal 
tubule handling of water and solutes, without renal deficiency 
Renal Disease with Urinary Tract Syndromes which'arises fi*om infection, 
obstruction and kidney stones
Asymptomatic Urinary Abnormalities : defined as abnormalities in urinary 
protein excretion or in the urinary sediment that originate Jfrom the kidney, 
without renal insufficiency or urinary tract symptoms 
Hypertension of Renal Origin : defined as sustained elevation of arterial 
blood pressure as the result of diseases of the renal parenchyma or major 
blood vessels
Asymptomatic Radiologic Abnormalities : defined as renal structural 
abnormalities observed on radiologic studies, without renal insufficiency, 
urinary tract symptoms, urinary abnormalities or hypertension
2.5 The ELISA Method
The antigen specific ELISA is an immunological configuration used to 
measure antibody activity in serum, secretions or culture fluids to a particular 
antigen (82). The concept is combining either antibody or antigen to 
spontaneously adsorb on polystyrene, polypropylene or polyvinyl permitted 
plastic reaction vessels to serve as solid phases for either antigen or antibody 
assays (83).
After incubation of the antigen or antibody with the microtitre plate.
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excess antigen was washed off and the prospective antibody or antigen 
containing fluid was added. Although microplates allow simple adsorption and 
are convenient, there can be undesirable effects. Where the antigen coated 
solid phase was incubated with the potential antibody-containing specimen, 
efforts were made to prevent antibodies and particularly other 
immunoglobulins, from adsorbing directly onto the solid phase while 
permitting antibodies to bind the antigens. This was accomplished by adding 
the non-ionic detergent Tween 20 and/or the abundant protein gelatin to 
reaction buffer phosphate buffered saline.
After a suitable incubation time, the plate was again emptied, washed 
and the solid phase complex was incubated with the antibody-enzyme 
detection system, HRP. Finally, an appropriate substrate for the enzyme used 
was added and the extent of reaction, which was stopped by sulphuric acid, 
was measured after some fixed time period by determining the absorbency of 
the coloured product.
Sandwich ELIS As, which measure antigen quantity, are performed by 
immobilising capture antibodies on a microtitre plate, then adding the 
prospective antigen containing fluid. They are 10 to 100 times more sensitive 
than competitive assays (84).
2.6 Purification of complement component C lq
Purified complement components are plasma (serum) fractions
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containing a high activity o f the required component and low content of other 
proteins. On dilution these fractions behave as single components.
The preparation o f purified C lq  involved re-calcifying one unit of 
plasma (obtained from the blood transfusion service at Law Hospital) by 
adding 4ml of IM CaCL and stirring this overnight at 4'° C. This was 
centrifuged at 4° C at 2000 rpm the next day for 15 minutes after which the 
supernatant was taken off and the pellet was discarded. The supernatant was 
now equivalent to serum.
125 ml of the serum was cooled in an ice bath (brought to 0 ° C by 
the addition of solid NaCl). One part volume of the serum was diluted with 
pH adjusted to 7.5 with either IM hydrochloric acid or IM  NaOH. The serum 
was then dialysed for 4 hours at 2 ° C against 1 litre EGTA (26mM/l, pH 7.5), 
the conductivity being equivalent to NaCl (30mM/l). The dialysis sac 
containing the serum was then dialysed against 1 litre of the same buffer for a 
further 11 hours.
The precipitate was harvested by centrifugation at 10 OOOg for 30 
minutes at 2 ° C and washed once with EGTA (26mM/l, pH 7.5) then dissolved 
in 32 ml o f acetate buffer (20mM/l, pH 5) containing 0.75M/1 NaCl and 
lOmM/1 EDTA. Insoluable aggregates were removed by centrifugation at 
10 OOOg for 30 minutes at 2° C.
The centrifuged supernatant was dialysed for 4 hours at 2 ° C 
against 41itres o f EDTA (60mM/l, pH5, RSC 65mM/l). The precipitate was 
harvested by centrifugation at 10 OOOg for 30minutes at 2 ° C,  washed 
once in EDTA(60mM/l, pH5) and dissolved in 32 ml PBS (5mM/l, pH7.5)
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containing NaCl (750mM/l) and EDTA (lOmM/1). Insoluble aggregates were 
removed by centrifugation (10 OOOg for 30minutes at 2° C).
Finally, the re-dissolved precipitate was dialysed at 2 ° C for 5 hours 
against 4 litres of EDTA.
2.6.1 Measurement of C lq  protein concentration
The protein concentration of the purified C lq was determined by 
measuring absorbency using the extinction coefficient s '^^cm = 6.8 at 280nm 
for C lq  (85). This was performed using a spectrophotometer.
2.6.2 Double-diffusion technique to determine quality of purified C lq
The double- diffusion technique relies on the fact that when antiserum 
and antigen are placed in adjacent wells in agarose gel they each diffuse out 
from the wells. At the point where antigen and antibody meet in optimal 
proportions (equivalence) a line o f precipitate develops.
A glass plate (80 mm x 80 mm) was cleaned by boiling for 10 minutes, 
then washed in de-ionised water, rinsed in alcohol and allowed to dry. A 
similar sized piece o f gel bond was applied to the plate. The plate was then 
covered with 10ml of molten 1.5 % agarose in veronal buffer and allowed to 
solidify.
Six wells were then arranged around a central well, the wells being 3 
mm in diameter and the distance between the centre of the central well and the 
centre of the peripheral wells being 10 mm. The central well was filled with 
purified C lq  and the rest o f the wells were filled with C lq  antiserum (Diasorin 
Code 80274) at various dilutions and anti-whole human serum (SAPU 5044).
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The gel was then placed in a glass humidity chamber on a horizontal surface at 
room temperature for 3 days. The gel was viewed using incident light against a 
dark background.
2.6.3 Electrophoresis method to determine the quality of purified C lq
Agarose gel electrophoresis was used to separate any proteins present 
in the purified C lq  into distinct, well-defined zones. The proteins in the gel, 
when placed in an electrical field, will migrate towards one o f the electrical 
probes.
The purified C lq  was then electrophoretic ally separated six times on 
the same gel. A different antiserum was overlaid directly onto the gel surface 
along the axis of each electrophoretic migration except the first one, which 
was overlaid with a protein fixative. The antisera applied were antisera to Clq, 
C3, C4, kappa and lambda. The resulting antigen-antibody complexes became 
trapped in the pore structure of the gel. The gel was then dried and stained to 
reveal protein precipitin bands and protein reference electrophoretic pattern. 
Interpretation was made by visually comparing the specific precipitin bands 
with the reference protein electrophoretic pattern.
2.7 Measurement of C lq  levels
A direct sandwich ELISA (Enzyme-Linked Immunosorbent Assay) system 
was used for the detection of C lq  in human serum. Specific IgG antiserum to
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C lq was coated onto high binding plates (Immunol 4), the sample applied and 
detected using the same specific antiserum conjugated to Biotin-avidin-HRP. 
Biotin-avidin system was utilised to increase sensitivity and also because of 
the lack of commercially available HRP conjugated antibodies to Clq.
In order to obtain biotin conjugate o f antiserum to C lq, the following 
procedure was carried out. 1ml o f antiserum was dialysed against 2 litres of 
PBS overnight. The protein concentration was then measured to ensure it was 
not greater than 5 mg/ml.
2.3mg Biotinamidocaproate dissolved in lOOp.1 o f dimethylformamide 
was added to the dialysed antiserum and left to stand at room temperature for 
2 hours with occasional shaking. It was then dialysed against 4 litres of PBS 
overnight and stored at 4 C.
The measurement of C lq  levels using the ELISA system was carried 
out as follows ;
an ELISA plate was coated, lOO/zl/well, with C lq  antiserum diluted to a 
concentration of 5/rg/ml in O.IM Na2 COs ,0.1M NaHCOs , pH 9.6 buffer and 
left to incubate overnight at 4'  ^C. The plate was then washed 3 times in 0.05% 
Tween in PBS and then blocked by adding 200/r 1/well o f 0.1% gelatin in PBS 
containing 0.05% tween for 1 hour at room temperature.
8 standard dilutions were made by making an initial dilution of normal 
human serum (SAPU, Law Hospital, Carluke) of 1/10 000 and doubly diluting 
until reaching 1/1 280 000 from which a standard curve is finally drawn. Test 
samples and a normal control were diluted at 1/10 000, 1/20 000 and 1/40 000. 
All dilutions were made in blocking buffer/ 0.086M EDTA. The plates were 
then washed 3 times in PBS/Tween. Standard curve samples were applied in
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duplicate while test samples were applied in triplicate at 100^1/well and left to 
incubate at room temperature for 2 hours. The plate was then washed and 
100/rl/well of 5^g/ml Clq. antiserum conjugated to Biotin diluted in blocking 
buffer to 1/5000 was added and incubated for 1 hour at room temperature. 
After washing, 100^1/well of avidin HRP diluted to 1/5000 in blocking buffer 
was added and incubated at room temperature for a further hour. After a final 
wash, lOOjuPwell o f developing biiffer (0.4mg/ml OPD in citrate- 
phosphate buffer, pH5.0, containing 4/rl/ral of 3% hydrogen peroxide) was 
added and the reaction was stopped by 4N H2SO4,
The plate was then read at 490nm on a Dynatech MXR ELISA plate
reader.
2.8 ELISA method to measure antibodies to C lq
Most studies have modified the solid phase C lq  binding assay for the 
measurement of antibodies to C lq  into an enzyme linked immunosorbent 
assay (ELISA) for the measurement of antibodies to C lq  in which either 
whole, or the collagen-like region of C lq  was employed (58,62,63). One 
pitfall in the measurement of antibodies to C lq  is possible interference by 
binding of immune complexes in assays using whole C lq. This may be 
inhibited by using high ionic strength conditions in the incubation media. In 
1990, complete inhibition of binding of immune complexes was demonstrated 
when the sodium chloride concentration used exceeded 0.15 M (46).
A second pitfall in IgG antibodies to C lq  measurement is the binding 
of immune complexes containing small native ds-DNA fragments to the
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collagen-like region of C lq  which could give false positive results by IgG 
anti-dsDNA bound to C lq  (86,87). This was also shown to be prevented by 
high ionic strength incubation medium (88,89). Notably binding o f antibodies 
to C lq  to C lq  was shown not to be affected by high ionic incubation medium, 
therefore antibodies to C lq  measurement should always be performed under 
high ionic strength conditions (36,86,50,90,91).
A third pitfall in IgG antibodies to C lq  measurement may be cross 
reactivity with C lq  by anti-collagen antibodies. Proteolysis by collagenase or 
exposure to oxydation of C lq  may reveal epitopes on the collagen-like region 
of C lq  that may also occur on collagen type H (92,93). IgG autoantibodies to 
collagen are present in the serum of SLE patients (94). This issue is addressed 
in 3.1.2. An ELISA plate was coated 100^1/well with purified C lq  diluted to a 
concentration o f 11/rg/ml in O.IM Na2C0 3 , O.IM NaHCO], pH 9.6 and 
incubated overnight at 4°C. The plate was then washed 3 times in 0.05% 
Tween in PBS and blocked by adding 200/j,l/well of 1% complement depleted 
foetal bovine serum in PBS containing 0.05% tween and IM  NaCl for 1 hour 
at37°C.
8 standard dilutions were made by making an initial dilution of 1/200 
and doubly diluting until reaching 1/12800. Test samples and a control were 
diluted at 1/200. All dilutions were made in the above blocking buffer, again 
containing IM  NaCl (high ionic strength to prevent IgG anti-dsDNA bound to 
Clq).
The plate was then washed 3 times. All samples were applied at 
100ja 1/well and left to incubate for 2 hours at 37 °C. The plate was then 
washed 3 times and lOOptl/well of rabbit anti-human Ig/HRP conjugate at a
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dilution of 1/1000 in blocking buffer was added and incubated at 37°C for 1 
hour. After a final wash, 100;/1/well of reaction substrate was added 
comprising of 0.4 mg/ml OPD in citrate-phosphate buffer, pH 5.0, containing 
4jul/ml of 3% hydrogen peroxide. The reaction was stopped with 50/xl/well 
4Nsulphuric acid and the optical density was read On Dynatech MXR at 
490nm.
2.9 ELISA method to measure anti DNA antibodies
Autoantibodies associated with the disease SLE mostly target 
intranuclear nucleic acids, proteins and RNP complexes and are called 
antinuclear antibodies (ANA). ANA is a test for any auto antibody that binds to 
non-specific antigens within a cell. One of the specific antigens, however, is 
double stranded DNA and a more specific test is needed to determine the 
presence of antibodies to dsDNA.
The genetic information of all living organism is contained in 
deoxyribonucleic acid (DNA). DNA forms a double stranded helix when intact 
because it pairs complementary bases on each strand and is carried on 
chromosomes. There are 3 forms of DNA which are antigenic in SLE : single 
stranded (ssDNA), double stranded (dsDNA) and left handed (zDNA).
Antibodies to dsDNA are detected in approximately 60% of patients 
with SLE. In general, antibodies to dsDNA levels reflect disease activity, but a 
lot of exceptions make antibody levels of limited value in many patients. For 
example, the strongest clinical association of antibodies to dsDNA has been 
with nephritis, although patients may have high levels of antibodies to dsDNA 
without renal disease.
53
A commercial kit (Cambridge Life Sciences Code M4196) was used to 
measure antibodies to double stranded DNA titres. Test samples, a reference 
standard and controls were diluted 1:100 in sample diluent, prediluted 
standards (0-800 lU/ml in increasing concentration) were all added lOOpl/well 
to a U-shaped well microplate. An antigen coated micropin lid was then placed 
on top of the microplate, with the tips of the pins immersed in the samples and 
incubated for 15 minutes. 100 pi/ well of conjugate was added to a second U- 
shaped well microplate. The micropin lid was then washed and the pins 
immersed in the conjugate filled plate for 15 minutes. 200 pi/ well of substrate 
was then added to a flat-bottomed microplate, the micopin plate was washed 
and added to this plate. Finally, the micropin plate was discarded and 50 pi / 
well of 4M sulphuric acid was added to the flat-bottomed plate. The optical 
density was measured at 490nm on a Dynatech MRX microplate reader.
2.10 ELISA method to measure antibodies to C Reactive Protein
An ELISA plate was coated lOOpl/well with C Reactive Protein 
(Sigma Cat No.9007-41-4) diluted to a concentration of 2.5 pg/ml in O.IM 
NaaCOa, O.IM NaHCO], pH 9.6 and incubated overnight at 4°C. The plate 
was then washed 3 times in 0.05% Tween in PBS and blocked by adding 
200pl/well of in PBS containing 0.05% Tween and incubated for 1 hour at 
37°C.
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8 standard dilutions were made by making an initial dilution of 1/200 
and doubly diluting until reaching 1/25600. Test samples and a control were 
diluted at 1/200. All dilutions were made in the above blocking buffer.
The plate was then washed 3 times. All samples were applied lOOpl/well and 
left to incubate for 1 hour at 37 °C. The plate was then washed 3 times and 
lOOpl/well of rabbit anti-human Ig/HRP conjugate at a dilution of 1/1000 in 
blocking buffer was added and incubated at 37 °C for 1 hour. After a final 
wash, 100p 1/well of reaction substrate was added comprising o f 0.4 mg/ml 
OPD in citrate-phosphate buffer, pH 5.0, containing 4pl/ml of 3% hydrogen 
peroxide. The reaction was stopped with 50pl/well 4N sulphuric acid and the 
optical density was read on Dynatech MXR at 490nm.
2.11 Measurement of C3d levels
The C3d-ELISA provides a very sensitive technique for the evaluation 
of complement activation in biological fluids.
2.11,1 Preparation of C3d standard
A C3d standard was derived from SAPU normal human serum by 
incubation with 3mg/ml of inulin at 3 7 °C for 1 hour, producing exhaustive 
activation o f the alternative pathway C3 convertase. This was centrifuged at 
1500xg for 30 minutes and then the supernatant was aliquoted and used as a 
C3d standard.
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2.11.2 C3d measurement by Double Decker Rocket Immunoelecrophoresis (DDRIE) 
For C3d analysis the blood to be tested was collected in sample bottles 
containing EDTA to prevent falsely elevated results due to breakdown 
products created by the coagulation process. EDTA also inhibits complement 
activation by chelating Ca and Mg ions which are essential components of the 
complement cascade. The samples were stored at -70 °C to avoid “in vitro” 
complement activation during storage.
The DDRIE method involves antiserum being incorporated into 
agarose and wells being cut into the agarose to hold the antigen. When an 
electric current was applied the antigen migrates towards the anode. At first, 
soluble complexes are formed in antigen excess, but as the antigen migrates 
further it becomes more dilute. Eventually, equivalence is reached and an 
insoluble precipitate is formed. The precipitate redissolves and moves forward 
as the antigen reaches it and finally, when no more antigen remains to enter 
the precipitate, a stable arc is formed which becomes stationary. The area 
under the rocket is proportional to the concentration of the antigen.
Activation of the classical pathway, or alternate pathway, results in 
breakdown of C3 with the formation of C3d. In order to separate any C3d 
from native C3, electrophoresis is carried out in a two tier agarose gel. The 
first tier contains anti-C3c to remove native C3 and breakdown fragments 
except C3d. Free C3d then enters the anti-C3d gel, where the size of the 
rocket formed is proportional to the concentration of the C3d.
A glass plate was covered with a sheet of gel bond and had molten 
neutral 1% agarose, molten 1% agarose mixed with C3c antiserum and molten 
2% agarose mixed with C3d antiserum and 8% polyethylene glycol(PEG)
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poured onto it. When the gel had solidified a row of 3mm holes were cut using 
a gel punch.
A C3d standard was derived from normal human serum (obtained from 
SAPU, Law Hospital, Carluke) by incubation with 3mg/ml of inulin at 37 °C 
for 1 hour, producing exhaustive activation of the alternate pathway C3 
convertase. Following centrifugation at ISOOxg for 30 minutes, the supernatant 
was removed and used as a standard. This standard was given an arbitrary 
value o f 250 units/ml. A standard curve was derived by diluting the standard 
in PBS to give arbitrary values of 50, 25, 18.2, 12.5 and 5 U/ml.
The plate was placed in an electrophoresis tank and two Cambrelle 
wicks were moistened with the PBS in the tank and placed in contact with the 
edges. Then a low current 15-24Vwas passed through the plate to help 
minimise lateral diffusion. 5jil of test and standard serum were put into the 
wells, after which the voltage was increased to 40V for 18 hours.
The plate was then removed from the electrophoresis chamber, covered 
with blotting paper and dried. The dried film was placed in Coomassie Blue 
stain and then placed in alcohol to remove excess stain. The fihn was allowed 
to air dry.
2.11.3 C3d-ELISA method
Microtitre plates were coated with 100;/1/well o f rabbit anti-human 
C3d diluted to a concentration of 1/xl/ml in PBS. Plates were then stored at 
4°C  for 24 hours, followed by incubation at 37°C for 1 hour with 100;il/well 
o f 1% foetal bovine serum in PBS to eliminate non-specific binding to the 
plastic wells.
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100//l/well o f the standard and each of the test samples were added to 
an equal volume o f 22% polyethylene glycol (PEG)2000 in PBS. Following 
incubation for 1 hour at 4°C , the mixture was centrifuged at ISOOxg for 30 
minutes at 4° C. This manoeuvre precipitates native C3 and related molecules, 
leaving C3d in the supernatant. The supernatant o f the standard was diluted in 
PBS containing 0.01% foetal bovine serum to a concentration of 1/500 and 
then doubly-diluted to a final concentration of 1/64 0000 to obtain a standard 
curve. The supernatant of the plasma of the test samples were diluted in PBS 
and tested at a concentration of 1/500. All were added at 100//1/well and 
incubated at 37 ° C for 1 hour.
Plates were then washed 3 times in PBS and 100//1/well of 
horse-radish peroxidase-conjugated rabbit anti-human C3d (Dako P0387) 
diluted 1/2000 in PBS added to each well for 45 minutes at 37° C. After 3 
more washes in PBS, 100//1/well of reaction substrate was added comprising 
of 0.4mg/ml OPD in citrate-phosphate buffer, pH5.0, containing 4//1/ml of 3% 
hydrogen peroxide. The reaction was stopped by 50//1/well 4N sulphuric acid 
and the optical density was read at 490nm.
58
Chapter 3
3 Results
3.1 The role of antibodies to C lq  in inflammatory disease
The C lq  molecule, altered by the inflammatory process, may generate 
antibodies capable of forming immune complexes. These immune complexes 
are often seen in inflammatory disease.
An investigation was carried out to determine if antibodies to C lq  of 
various Ig isotype are associated with inflammatory disease. Initially, C lq, to 
be used as an antigen, had to be isolated and purified. Then a method, using 
ELISA to measure antibodies to Clq, had to be developed.
3.1.1 Purification o f C lq
Using the extinction coefficient = 6.8 at 280nm for C lq, the final 
volume obtained from plasma using the purification of C lq  method described 
in 2.6.1 was diluted to a concentration of Img/ml, employing a 
spectrophotometer.
3.1.1.1 Double - diffusion method to determine the quality and provide
evidence o f purified C lq
Precipitins were formed between the purified C lq  and the C lq  
antiserum at all dilutions, the strongest at 1:1, the next strongest at 1:2, and the 
weakest at 1:4 (Figure 3.1.1.1).
No precipitins were formed between the anti-whole human serum and 
the purified C lq.
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3.1.1.2 Electrophoresis method to determine the quality of the purified C lq
The electrophoresis gel (figure 3.1.1.2) showed a single protein band in 
the protein-fixed migration. Protein analysis by immunofixation with C lq 
antiserum and C3, C4, kappa and lambda antisera identified this band as Clq. 
Immunofixation with C3, C4, kappa and lambda showed no discernible bands.
In conclusion, the purified C lq  was free from other major serum 
proteins.
3.1.2 Determination of cross-reactivity with C lq by anti-collagen antibodies
A cross-reacting antibody is capable of combining with an antigen 
which did not specifically stimulate its production. The antigen for GMB 
antibodies is part o f the glomerular basement membrane mainly consisting of 
different collagen chains (95). C lq  has a collagen-like region. Because 
glomerular basement membrane (GBM) contains collagen, it was determined 
whether two commercially available blood serum samples containing 
antibodies to GBM (collagen) were positive for antibodies to C lq. If so, then 
cross-reactivity exists. The results are shown in Table 3.1.2.
The samples containing anti-collagen antibodies were negative for 
antibodies to C lq  so there is no cross reactivity between antibodies to GBM 
and Clq.
3.1.3 Measurement of antibodies to C lq
3.1.3.1 Determination o f standards and normal ranges
A serum of known arbitrary value for IgG antibodies to C lq , i.e. 1241 
U/ml (from Professor Daha, Department of Nephrology, University Hospital,
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Leiden, The Netherlands calculated using the method described in (40)) was 
used as a known value standard. A checkerboard technique, where the sample 
was tested at different sample, plate coating and conjugate dilutions, was 
employed to determine the optimum conditions for the standard curve. The 
values of IgG antibodies to C lq of serum from 27 healthy donors were 
obtained. In order to establish a normal range for IgG antibodies to C lq, the 
mean titre + 2 standard deviations of the serum samples of these healthy 
donors was regarded as the upper limit of normal levels. The levels are listed 
in Table 3.1.3.1.
The mean was found to be 71 U/ml, the standard deviation 42 U/ml, 
therefore the upper limit of normal was calculated to be 155 U/ml.
There are no agreed standard sera for IgA and IgM antibodies to Clq, 
therefore the normal ranges for these antibody isotypes was obtained by 
testing high titre IgG antibodies to C lq  positive sera for corresponding IgA 
and IgM activity. This was done by an ELISA “checkerboard” technique. The 
optical densities of serum from 5 normal controls and 5 patients with high titre 
IgG antibodies to C lq  were measured. In both cases the serum with the 
highest optical density was chosen for use as a standard for each isotype. Each 
of these standards was given an arbitrary value of 100 U/ml. The IgA antibody 
titres to C lq  and IgM antibody titres to C lq  of 30 healthy donors were 
measured using ELISA technique. The mean titre + 2 standard deviations was 
considered the upper limit of normal. The levels are listed in Table 3.1.3.1 and 
the mean for IgA antibodies to C lq  was found to be 22 U/ml, the standard 
deviation 25, so the the upper limit of normal was 72 U/ml. The mean value 
for IgM antibodies to C lq  was 44 U/ml, the standard deviation 28 and the
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upper limit of normal 100 U/ml. Any value greater than the upper limit of 
normal was considered to be significantly raised.
3.1.3.2 Comparison of antibody titres to C lq  in normal healthy donors and patients 
with inflammatory disease
Antibodies to C lq  may form immune complexes which, in turn, 
perpetuate inflammation. This study tries to determine if patients with 
inflammatory disease have a higher than normal level of antibodies to Clq.
In order to determine whether patients with inflammatory disease had 
higher antibody titres to C lq  than normal, 64 patients with inflammatory 
disease were tested and the results are shown in Table 3.1.3.2. The antibody 
titres to C lq  of different isotype in serum samples of these patients, and 
normal healthy donors, was compared. There was no statistical significance in 
IgG antibody titres to C lq  found in patients with inflammatory disease when 
compared with normal healthy donors but IgA and IgM antibody titres to C lq 
were found to be significantly lower. These findings prompted further 
investigations to determine if  there were differences in titres between types of 
inflammatory disease.
The patients were then subdivided into groups of disease categories : 
SLE, RA and HAID. The antibody to C lq  levels in each of these categories 
was compared to those of normal healthy donors and the results shown in 
Table 3.1.3.2. IgG antibody titres to C lq  were significantly higher in patients 
with SLE when compared to normal healthy donors, while IgA antibody titres 
to C lq were significantly lower in RA patients. IgM antibody titres to C lq
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were significantly decreased in all three disease categories. These results 
suggest differences in titres of antibodies to C lq depend on type of disease and 
immunoglobulin isotype.
3.1.3.3 Correlation o f serum antibody titres to C lq  with age (range 17-89 years) and 
with biological markers of autoimmune disease activity in patients with 
various autoimmune inflammatory diseases
Associations of antibody titres to C lq with biological markers of 
autoimmune disease activity and age would imply antibodies to C lq  may 
contribute to disease activity. This may show measurement of antibody titres 
to C lq  as a possible diagnostic tool for determining inflammatory disease. The 
aim was to investigate whether associations exist. The biological markers 
included anti-nuclear antibodies, anti-double stranded DNA antibodies, 
complement C3, C4, C l inhibitor and C lq  level. 64 patients with 
inflammatory disease were tested and the results are shown in Table 3.1.3.3.a.
No significant correlations were found except for IgA antibodies to 
C lq  which were found to be correlated with titre of antibodies to double 
stranded DNA.
The patients were subdivided into groups of disease categories, SLE, 
RA and HAID and the results are shown in tables 3.L3.3b-d.
At p < 0.05 there were correlations of antibodies to C lq  with age and 
IgA antibodies to C lq  with ANA in SLE patients, IgG antibody titres to C lq 
with C3 and C4 and IgM antibodies to C lq  with age in RA patients, and also 
IgM antibody titres to C lq  with Cl inhibitor. In HAID patients IgG antibody
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titres to C lq  were significantly correlated with age and C l inhibitor 
concentrations, and IgA antibodies to C lq  with C4 and Cl inhibitor 
concentrations.
Patients with HAID appear to produce more IgG antibodies to C lq  as 
they get older and when there is a high level o f in C l inhibitor. They also have 
high levels of IgA antibodies to C lq  when there is a high level of C4 and Cl 
inhibitor present.
While these results suggest there is an association between antibody 
titres to C lq  of certain immunoglobulin isotype and age and various biological 
markers of disease activity, they are not conclusive evidence that antibodies to 
C lq  contribute to inflammatory disease in general.
3.1.3.4 Correlation of biological markers o f autoimmune disease activity in patients 
with inflammatory disease
After finding that correlations existed between antibodies to C lq  and 
other complement components, it may be useful to determine whether there 
were associations between the individual markers to try and ascertain their 
possible influence on inflammatory disease. The results for inflammatory 
diseases, SLE, RA and HAID are shown in Tables 3.1.3.4a-d respectively. 
Results of p< 0.01 were considered significant.
C3 was correlated with C4 in patients with inflammatory diseases, SLE 
and RA, but not HAID. Cl inhibitor again featured in HAID patients 
correlating highly significantly with C3 and also with C3 and C4 in RA. In
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patients with SLE, antibodies to double stranded DNA correlated with C l 
inhibitor and C lq  level.
Generally, inflammatory disease appears to affect the levels of C3, C4 
and C l inhibitor.
3.1.3.5 Comparison of some complement component levels of patients with 
autoimmune inflammatory diseases
The correlations found between certain complement components 
where inflammatory disease appeared to affect the levels of C3, C4 and Cl 
inhibitor prompted this investigation. The levels of these components in 
patients with autoimmune inflammatory disease were compared to normal and 
to each other and the results are shown in Tables 3.1.3.5a-b.
There was a significant correlation of SLE with HAID and RA with 
HAID in C3 which suggests that this complement protein is consumed due to 
inflammatory disease.
A very high proportion of HAID patients (12/14) had low C3. This 
suggests that low C3 may be a characteristic of patients with HAID and that 
they consume large amounts o f C3. Activation of C3 causes swelling of blood 
vessels, known as vasodilation, which leads to inflammation, which in turn 
stimulates C3 activation. HAID patients may have chronic inflammation 
which stimulates a constant turnover of C3 therefore leading to the low levels 
observed.
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3.1.3.6 Comparison of the antibody titres to C lq  in serum samples of 2 groups of 
patients ; one group with normal levels, and one group with increased titres of 
antibodies to double stranded DNA
Increased levels of antibodies to double stranded DNA are 
characteristic of patients with SLE (96) and are associated with IgG antibodies 
to C lq  (35) but less is known about their association with IgA and IgM 
antibodies to Clq.
The aim of tliis section is to determine if  there was a quantitative 
relationship between IgG antibodies to C lq  and antibodies to double stranded 
DNA. A further aim is to examine whether such a relationship applied to the 
IgA and IgM isotypes o f antibodies to C lq  because a significant correlation 
was found between IgA antibodies to C lq  and antibodies to double stranded 
DNA in patients with inflammatory disease (3.1.3.3). Since a positive result 
for antibodies to double stranded DNA is a criterion from the ACR criteria for 
the classification of SLE, then a comparative increase of antibodies to double 
stranded DNA would suggest antibodies to C lq  could also become a criterion 
of SLE.
The serum of 39 patients with increased titres of antibodies to double 
stranded DNA and 39 patients with normal tittres of antibodies to double 
stranded DNA titres were tested for antibodies to C lq  (Table 3.1.3.6). IgG 
antibody titres to C lq  were found to be significantly higher in patients with 
increased antibodies to dsDNA titres compared to antibodies to dsDNA 
normal patients. There was no significant difference in IgA antibodies to C lq  
or IgM antibody titres to Clq.
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There appears to be a relationship between increased IgG antibodies to 
C lq  and antibodies to double stranded DNA.
A relationship has been established between antibodies to C lq  and 
antibodies to double stranded DNA, and therefore with inflammatory disease. 
Since C reactive protein (CRP) binds avidly to DNA immune complexes from 
dead and damaged cells and the anti-inflammatory effects of CRP requires the 
presence o f C lq  (97), further studies should include associations o f antibodies 
to CRP with inflammatory disease.
3.2 The role o f antibodies to CRP in inflammatory disease
Apoptotic cells are cells which are genetically programmed to die. 
They cleave their DNA into small fragments by their own enzymes. C reactive 
protein (CRP) is an acute phase protein which is thought to promote the 
removal of nucleic acid and dead or damaged cells by phagocytosis. CRP may 
do this by binding to the DNA-histone complexes exposed in dead or damaged 
cells. After binding, CRP then activates the classical complement pathway via 
C l, thereby inducing all the known inflammatory, opsonising and complex 
solubilizing activities o f the complement system. All of these processes should 
reduce chronic inflammation (98,99,100).
Deficiency o f C lq  is the predominant cause o f both the impaired 
clearance of apoptotic cells and increased predisposition to spontaneous 
autoimmunity. Apoptotic cells are thought to be a major source of the 
autoantigens o f SLE (101). CRP is thought to carry out a similar immune 
complex clearance role to that of C lq  and the classical complement pathway.
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This thesis postulates that antibodies to CRP may be produced in 
response to increased levels of CRP and may inhibit the ability of CRP to 
carry out its immune complex clearance process. This could perpetuate 
inflammation which may lead to inflammatory disease.
An investigation was carried out to determine if  antibodies to CRP are 
associated with inflammatory disease. Initially, a method using ELISA to 
measure antibodies to CRP had to be developed.
3.2.1 Measurement o f antibodies to CRP
There were no standard sera available for IgG, IgA and IgM antibodies 
to CRP therefore an in-house standard serum was obtained. Sera of 24 patients 
with autoimmune disease was tested for IgG, IgA and IgM antibody activity to 
CRP using a checkerboard technique. This involved testing samples at 
different sample, plate coating and conjugate dilutions to determine the 
optimum conditions for the assay performance. The serum showing the most 
antibody activity for each isotype, i.e. the highest optical density, was chosen 
as a standard. Each of these standards was given an arbitrary value of 100 
U/ml. Suitable standard curves were obtained by double diluting the standard 
for each isotype and was used to measure the IgG, IgA and IgM antibody titres 
to CRP respectively.
A normal range was established using serum from 30 healthy donors 
and the levels are listed in Table 3.2.1. The mean titre + 2 standard deviations 
of these sera samples was regarded as the upper limit of normal.
The mean for IgG antibodies to CRP was found to be 23 U/ml and the 
upper limit 59 U/ml, the mean value for IgA antibodies to CRP to be 12 U/ml
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and the upper limit to be 28 U/ml and, the mean value for IgM antibodies to 
CRP to be 7 U/ml and the upper limit 24 U/ml. Any value greater than the 
upper limit of normality was considered to be significantly raised.
3.2.2 Comparison of antibody titres to CRP in healthy donors and patients with 
inflammatory diseases
Antibodies to CRP may reduce levels of CRP which, in turn, may 
perpetuate inflammation. This study tried to ascertain if  patients with 
inflammatory disease would show a higher than normal level o f antibodies to 
CRP.
64 patients with inflammatory disease were tested and the results are 
shown in Table 3.2.2. IgM antibodies to CRP were significantly higher than 
normal (p <0.05) while IgG and IgA antibodies to CRP were very significantly 
increased when compared with serum levels in normal healthy donors.
This suggests that antibodies to CRP may inhibit the immune role of 
CRP. These findings prompted further investigations to determine if there 
were increased titres between different types of inflammatory disease.
The patients were sub-divided into categories of disease : SLE, RA and 
HAID (Table 3.2.2). The antibody titres to CRP in each of these categories 
were compared to those of normal healthy donors. There were significantly 
higher antibody titres to CRP in all categories of patients. The antibody 
isotype was especially high for the IgG and IgA antibodies to CRP in SLE 
when compared to normal healthy donors. However, IgM antibodies titres to 
CRP in HAID patients was normal.
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The results suggest there is a direct link between increased antibody 
titres to CRP and inflammatory disease and therefore it appears increased 
antibodies to CRP may have a detrimental effect on the immune capabilities of 
CRP.
3.2.3 Correlation of serum antibody titres to CRP with age (range 17-89 years) and 
biological markers of autoimmune disease activity in patients with various 
autoimmune inflammatory diseases
The aim was to investigate if there was an association of antibody 
titres to CRP with biological markers of autoimmune disease activity (see 
below) and also if  there was an association of antibody titres to CRP with age. 
Any associations found would imply antibodies to CRP may contribute to 
disease activity. The biological markers included anti-nuclear antibodies, anti­
double stranded DNA antibodies, complement C3, C4, C l inhibitor and C lq 
level.
64 patients with inflammatory disease were tested and the results are 
shown in Table 3.2.3.a. IgG antibody titres to CRP were negatively correlated 
with age, C3 and C4. IgA was negatively correlated with C l inhibitor while 
IgM was positively correlated with antibodies to double stranded DNA.
The patients were then subdivided into groups of disease categories : 
SLE, RA and HAID and the results are shown in Tables 3.2.3b-d.
IgG antibody titres to CRP were negatively correlated with C3 and Cl 
inhibitor in HAID patients. IgA antibody titres to CRP were positively 
correlated with DNA and negatively with C3 and C4 in SLE patients and 
strongly correlated with Cl inhibitor in HAID patients. IgM CRP titres were
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positively correlated with ANA and antibodies to dsDNA in SLE patients and 
age in HAID patients. No correlations of any kind were found in RA patients.
Decreased levels of Cl inhibitor have been described in patients with 
autoimmune disease and this decrease was due to complement consumption 
(109). This present study showed that in HAID patients C l inhibitor levels 
decreased significantly as IgG and IgA antibodies to CRP levels increased. 
This suggests that these antibodies are associated with complement 
consumption in HAID patients.
The results suggest that, in SLE patients, as the level of antibodies to 
double stranded DNA increases, DNA immune complexes increase. This 
raises the level o f CRP which, in turn, generates IgM antibodies to CRP. In 
inflammatory disease, as levels of IgG antibodies to CRP increase C3 and C4 
levels decrease, suggesting that IgG antibodies to CRP induce complement 
consumption.
Measurement of intact components such as C3 and C4 provides only 
limited information concerning complement activation. The breakdown 
product C3d is a more useful indicator of complement breakdown and 
therefore further studies should include associations o f C3d level with 
inflammatory disease.
3.3 C3d as an indicator of inflammatory disease
Raised levels of C3d are an indicator o f increased complement 
activation. Since complement activation is thought to lead to inflammation, the 
aim of this part of the study is to investigate if there was an increased level of
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C3d in patients with inflammatory disease, which would show measurement 
of C3d as useful in diagnosing various inflammatory diseases. Initially, a 
method using ELISA to measure C3d level had to be developed.
3.3.1 Correlation of C3d ELISA levels in the plasma of patients with inflammatory 
disease with C3d DDRIE levels
A method using ELISA was developed, based on a method previously 
described (102), with the aim to provide a more accurate and quantitative test 
to measure C3d level in blood plasma than the traditional tried and tested 
Double Decker Rocket Immuno Electrophoresis (DDRIE) method.
A C3d standard was obtained as described in 2,11.2 and 2.11.3 and 
normal blood plasma were tested at different sample, plate coating and 
conjugate dilutions to determine the optimum conditions for assay 
performance. The C3d standard produced a far higher optical density value 
than the normal blood plasma suggesting the standard had a far higher 
concentration of C3d.
The standard was initially diluted to a concentration of 1/500 and 
doubly-diluted to a final concentration of 1/64 000 to obtain a suitable 
standard curve. The initial dilution was given an arbitrary value of 100 U/ml, 
the second dilution 50 U/ml and so on.
A normal range was established using plasma samples from 11 healthy 
donors. The mean titre +2 standard deviations of these samples were regarded 
as the upper limit o f normal. The mean for normal C3d level was found to be
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13 U/ml and the upper limit to be 33 U/ml. Any value greater than the upper 
limit of normality was considered to be significantly raised.
The results from measurement of 45 patients with inflammatoiy 
disease using both methods were compared in order to test the validity o f the 
newly developed C3d ELISA .The results are shown in Figure 3.3.1.
The data fi'om the ELISA method shows almost normal distribution 
whereas the data from the DDRIE method is skewed. Therefore, in order to 
normalise the data from the DDRIE method, the log DDRIE data was 
correlated with the ELISA data. However, the correlation co-efficient 
remained almost the same (0.352, p<0.05).
A significant correlation was found between the two methods 
suggesting the ELISA method was valid.
3.3.2 Comparison of C3d ELISA levels in the plasma of normal human donors and 
patients with inflammatory disease
Raised levels of C3d show evidence of complement consumption, 
which is associated with inflammation. The aim is to determine if raised C3d 
levels are indicative o f inflammatory disease.
Patients with inflammatory disease were tested as a whole and then in 
the three categories, SLE, renal disease and HAID, and the results are shown 
in Table 3.3.2. C3d levels were significantly higher in all the disease 
categories when compared to normal healthy donors. This suggests that 
increased complement activation is associated with inflammatory disease.
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Chapter 4
Discussion
Patients with increased levels of auto antibodies often have associated 
inflammatory disease. This . thesis tries to determine if  patients with 
inflammatory disease have a significantly different than normal level of 
antibodies to C lq, and of antibodies to CRP, and whether this depends on 
immunoglobulin isotype and on the type of inflammatory disease. Also 
investigated was whether there are associations of antibodies to Clq, and of 
antibodies to CRP with age and biological markers of autoimmune 
inflammatory disease such as anti-double stranded DNA antibodies and 
complement C3, C4, C l inhibitor. This thesis has demonstrated that ;
• differences in titres of auto-antibodies to C lq  and CRP depend on category 
of inflammatory disease and immunoglobulin type
• an association of antibodies to C lq  and antibodies to CRP of certain 
immunoglobulin isotype with age and various biological markers of disease 
activity
• patients with increased levels of antibodies to double stranded DNA tend to 
have increased levels of antibodies to C lq
• antibodies to C lq  and antibodies to CRP are strongly associated with Cl 
inhibitor in HAID patients
• in inflammatory disease, as levels of IgG antibodies to CRP increase, C3 
and C4 levels decrease
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there appears to be a direct link between increased antibody titres to CRP 
and inflammatory disease
inflammation increases production of C3d in the plasma 
generally, inflammatory disease appears to affect the levels o f C3, C4 and 
Cl inhibitor. In some diseases these levels are reduced in a co-ordinated 
manner suggesting consumption by the classical pathway. In others, raised 
levels may suggest increased synthesis as part of the acute phase pathway
Why study antibodies to C lq ?
Immune complexes consist of antibodies non-covalently combined 
with their corresponding antigens (103). They can deposit in tissues, activate 
the complement pathways and result in a series of inflammatory reactions 
(104).
Antibodies to C lq  have been demonstrated to contribute to the 
formation of circulating immune complexes (46). C lq  molecules bound by 
immunoglobulins that are part o f an immune complex are potential antigens 
for antibodies to C lq. Antibodies to C lq may amplify the formation of 
immune complexes by increasing immune complex size. If  these circulating 
immune complexes are trapped, inflammatory reactions can occur (105).
Measurement of antibody titres to C lq may become a valuable tool for 
the clinical management of patients with inflammatory disease.
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Why study antibodies to CRP?
CRP serum levels increase during inflammation which is thought to 
promote opsonisation, enhance phagocytosis and stimulate leucocyte motility 
(106). It was postulated that increased levels of antibodies to CRP may inhibit 
the ability of CRP to carry out the above immune processes therefore causing 
prolonged diseases such as systemic lupus erythematosus and rheumatoid 
arthritis. This thesis tries to ascertain if  there is also an increased presence of 
antibodies to CRP in patients with systemic lupus erythematosus and 
rheumatoid arthritis which would show a correlation between antibodies to 
CRP and inflammation.
Why study C3d levels?
Activation of the complement cascade is of importance in the 
pathogenesis of immune damage in rheumatoid arthritis and SLE (107). 
Levels of complement C3 may be normal or raised in the presence of 
complement consumption. Since C3 behaves as an acute phase reactant in 
rheumatoid arthritis, and low levels of C4 are often genetically determined by 
the possession of C4 null allelic variants (108), then the measurement of 
fragment C3d, a product of complement breakdown o f both the classical and 
alternative pathways, was considered to be a more reliable method of 
determining complement activation.
This study tries to develop an ELISA method which would be a more 
quantitative and sensitive than the traditional DDRIE method and then, using 
this ELISA method, to determine if there was a higher than normal level of 
complement activation in patients with SLE and renal disease.
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4.1 Antibodies to C lq  in patients with inflammatory disease
In order to determine the level o f antibodies to C lq  present in the 
blood sera of the normal healthy donors and the patients, the C lq, to be coated 
onto the ELISA plates, had to be as pure as possible.’When antiserum and 
purified C lq are placed in adjacent wells in an agarose gel, they diffuse out 
from the wells and form a line of precipitate at the point where antigen and 
antibody meet (109). As precipitins were formed between all three dilutions of 
the purified C lq, including the weakest dilution, then it follows that the test 
sample contained a high concentration o f C lq. Analysis by serum protein 
electrophoresis showed the purified C lq  to be free from other main serum 
proteins, indicating a high a level of purity.
Because C lq  has a collagen-like region, there was a concern that 
antibodies to collagen (not antibodies to C lq) m aybe combining with Clq, i.e. 
cross reactivity, and therefore would give a falsely positive result. Glomerular 
Basement Membrane (GBM) consists o f collagen chains and antibodies to 
GBM are antibodies to collagen. The investigation in this study shows there is 
no cross reactivity with these antibodies to collagen. This may be because the 
collagen-like region of C lq  may be similar to collagen type II (92,93) while 
the only antigen significant for GBM antibodies is collagen type IV (111). 
However, serial measurement by 2 assays of antibodies to C lq  and collagen 
autoantibody titres in the same cohort of SLE patients showed separate disease 
associations for each autoantibody, indicating that both assays probably detect 
different antibodies (111). In addition, either native C lq  or the collagen-like 
region of C lq  is used for the measurement o f antibodies to C lq  under
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standardised conditions, excluding the possibility o f proteolysis by 
collagenase. Consequently, it is unlikely that anti-collagen antibodies interfere 
in standardised assays used for the measurement of antibodies to C lq.
It was suggested in 1971 that C lq  bound to IgG in SLE (53) and 
antibodies to C lqs were proved to exist in 1984 (50).'Previous studies have 
found increased titres of IgG antibodies to C lq  in 56% (41), 49.4% (91), 34% 
(40) and 33% (112) of SLE patients.
hi 1993 it was found that the occurrence of increased IgA antibodies to 
C lq in SLE patients remained similar to that in individuals from the general 
population (64). The present study found similarly (P > 0.05). The findings in 
this study that IgG antibodies to C lq were found to be significantly increased 
in SLE is supported by previous studies (50).
Previously, IgG and IgA antibodies to C lq  were found in less than 5% 
of the sera from RA patients but found IgA antibodies to C lq  in 61% of 
patients with rheumatoid vasculitis (46). The present study found no 
significant increase in IgG antibodies to C lq  in RA patients.
IgM antibody titres to C lq  were very significantly lower in SLE, RA 
and HAID patients suggesting that inflammatory disease actually inhibits the 
generation o f IgM antibodies to Clq. This was also true o f IgA antibodies to 
C lq in RA.
In patients with SLE, IgG antibody titres to C lq  decreased with age. 
This observation agrees with a previous study (64) which also showed that in 
serum samples of individuals, randomly selected out o f the general population, 
IgG antibody titres to C lq  initially decreased and subsequently increased with 
age. The decrease in IgG antibodies to C lq  may be due to the fact that severe
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manifestations of SLE are mostly found in young patients (113) which 
suggests that IgG antibodies to C lq play a role in the pathogenesis o f SLE. 
IgA and IgM antibodies to C lq showed no significant correlation with SLE 
patients.
A previous study (64) found that IgA antibody titres to C lq  in serum 
of SLE patients and of randomly selected individuals were low and did not 
differ significantly between the different age groups. It was postulated that the 
increased production of auto antibodies in serum of individuals o f older age 
results in defects in the function of suppressor cells and originates from B-cell 
clones derived from stem cells in the bone marrow (114,115).
Antibodies to C lq  may amplify complement activation by immune 
complexes in tissues, by binding to C lq fixed to immune complexes, enlarging 
the complexes and promoting further activation (116).
In patients with rheumatoid arthritis, IgG antibody titres to C lq  were 
increased as the complement complements C3 and C4 decreased suggesting 
IgG antibodies to C lq  cause consumption of C3 and C4 leading to the chronic 
inflammation associated with RA. Patients with rheumatoid disease have low 
serum complement (117). Low C3 levels are less common and are a pointer to 
the presence of severe disease (118).
Results in this study show patients with HAID generate more IgG 
antibodies to C lq  as they get older. In the classical pathway C l inhibitor limits 
activation o f C l by blocking the C lr and C ls components. The highly 
significant correlation of IgA antibodies to C lq  with C4 and C l inhibitor, and 
IgG antibodies to C lq  with Cl inhibitor, conflicts with a previous study which 
found that decrease of C l inhibitor levels due to consumption were described
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in autoimmune diseases such as SLE (119). In contrast to IgG antibodies to 
C lq in RA, the levels o f C4 and C l inhibitor were raised in the presence of 
IgA and IgG antibodies to C lq  in patients with RAID. There is no clear 
explanation for this.
There was no evidence that IgA and IgM antibodies to C lq are 
associated with complement activation or inhibition in patients with SLE and 
RA. However, a negative correlation of IgM antibodies to C lq  with Cl 
inhibitor in patients with HAID shows Cl inhibitor may decrease in the 
presence of IgM antibodies to C lq  allowing complement activation.
There was a significant correlation between IgA antibodies to C lq  and 
antibodies to double stranded DNA in patients with inflammatory disease 
which prompted further investigation. This present study discovered that IgG 
antibody titres to C lq  were significantly increased in patients with increased 
titres of antibodies to double stranded DNA when compared to patients with 
normal antibodies to double stranded DNA levels.
Several reports have claimed a correlation between autoantibodies to 
double stranded DNA and disease activity (120,121,122) as well as a positive 
correlation between antibodies to C lq  and antibodies to double stranded DNA 
(35). This suggests that antibodies to C lq  develop as part of an autoantibody 
response to C lq  complexed with other lupus autoantigens and therefore the 
antibodies to C lq  may play a role in the pathogenesis of disease activity.
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4.2 Antibodies to C-Reactive Protein in Patients with Inflammatory disease
Many substances react directly with C lq in absence of antibody to 
activate the classical complement pathway. These include nucleic acids, 
proteins, lipids and polysaccharides (122).
CRP activates the classical complement pathway upon interaction 
with polycations as well as phosphorylcholine ligands independent of the 
presence of antibody, and induces complement-dependant opsonisation by 
neutrophils and monocytes as well as complement-dependant haemolysis by 
reactions which initiate at the level of C lq  ; like IgG, two molecules are 
required for activation (123,124).
CRP binds to apoptotic cells and augments the activation of the 
classical complement pathway. CRP and the classical complement 
components act together to promote non-inflammatory clearance o f apoptotic 
cells. The anti-inflammatory effects of CRP require the presence of C lq, 
indicating a pivotal role for the early complement components in this process. 
Deficiency of C lq  fails to protect apoptotic cells from lysis and permits the 
normally protective effect of CRP to perpetuate the inflammatory response. 
This impaired handling of apoptotic cells and increased necrosis predisposes 
individuals to autoimmune disease and autoimmune disorders such as 
SLE(97).
SLE is a relapsing disease, and whereas CRP increases during acute 
infections, patients with SLE paradoxically demonstrate low levels of 
CRP(125).
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This study found that patients with inflammatory disease had 
significantly higher titres of antibodies to CRP of all isotypes tested (IgG, IgA 
and IgM) in their sera when compared to normal healthy donors. The role of 
the complement system is to clear apoptotic, dead and dying cells from the 
tissues in the body. CRP is thought to carry out a similar'clearing role to 
complement and the increased levels of antibodies to CRP provides evidence 
that these autoantibodies may inhibit this role.
In general, patients with SLE and inflammatory disease showed 
evidence of associated low C3 and C4 with levels of IgA and IgG antibodies 
to CRP. Patients with HAID showed associated very low levels of C l inhibitor 
with high levels of IgG and IgA antibodies to CRP. These all suggest 
complement consumption. This disagrees with a previous study that found that 
antibodies to CRP strongly inhibit the interaction between CRP and C lq  and 
therefore inhibit complement activation (33).
However, the association of IgM antibodies to CRP with antibodies to 
double stranded DNA in SLE and inflammatory disease may be explained by 
antibodies to double stranded DNA being produced against DNA from 
apoptotic , dead and dying cells. The above association provides evidence that 
IgM antibodies to CRP may inhibit the ability of CRP to bind this DNA and to 
activate the classical pathway allowing clearance of the DNA complexes. This 
evidence supports the previous study (33).
Without efficient complement activation, there may be inefficient 
clearance of immune complexes. These immune complexes will deposit in 
tissues, and cause injury. This injury may cause the release o f autoantigens as 
an inflammatory reaction and augment the autoimmune response.
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One reason for resulting inefficient complement activation may be due 
to ongoing complement turnover, due to an autoimmune response, leading to 
depletion of complement components such as C3 and C4. However, while it is 
not known what antigen initially triggers the autoimmune process, there is 
evidence that apoptotic cells are the antigen (116).
4.3 C3d levels in Patients with Inflammatory disease
Measurement of levels of C3d in blood plasma are a more useful 
indicator of complement activation than measurement of C3 and C4 because it 
is produced as a result o f complement activation. This gives information 
which may be useful in the management of inflammatory disease where 
complement activation takes place may cause tissue damage.
In a comparison between the ELISA and DDRIE methods, a 
significant but weak correlation (p<0.05) was found. This suggests the ELISA 
technique was valid, but the weak correlation may be because the ELISA 
method is usually far more sensitive and quantitative than immuno- 
electrophoresis techniques such as the DDRIE method.
The ELISA technique was then used to measure levels o f C3d and 
found that patients with SLE, renal disease, HAID and inflammatory disease 
in general had increased levels of C3d. Therefore it can be concluded that 
complement activation is increased in patients with inflammatory disease.
If future studies could determine a correlation of abnormal levels of 
autoantibodies with increased levels of C3d, this would provide further 
evidence of the association of autoantibodies with inflammatory disease.
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Chapter 5
Conclusions
Differences in titres of antibodies to C lq  vary according to type of 
inflammatory disease, age and various biological markers o f autoimmune 
disease activity. There is a positive correlation between increased antibodies to 
C lq  and antibodies to double stranded DNA suggesting that antibodies to C lq 
develop as part of an autoantibody response to C l complexed with other 
autoantigens. Overall, antibodies to C lq  of different isotype correlate with 
some, but not all, autoantibodies. This would imply a causal link other than 
polyclonal activation of B-lymphocytes.
There was evidence of associated levels of C3, C4 and C l inhibitor 
with high levels of IgA and IgG antibodies to CRP suggesting induction of 
complement consumption. However, IgM antibodies to CRP may inhibit the 
clearing ability o f CRP, which would inhibit complement activation. IgM 
antibodies to CRP may bind with CRP at the site of apoptotic cells, preventing 
DNA-histone bound CRP from activating the classical complement pathway 
via C l.
Complement activation was increased in patients with inflammatory 
disease. This was evident because of the associated increased C3d levels in 
these patients.
The results show there is strong evidence that antibodies to C lq  and 
antibodies to CRP of certain immunoglobulin isotype form immune 
complexes which induce complement consumption. The resulting complement
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deficiency of C3 would impair the ability o f complement to clear immune 
complexes. An autoimmune response is then triggered and so the cycle goes 
on leading to chronic inflammation and inflammatory disease. Future studies 
should try to determine how and why this inflammatory cycle is initiated. 
Certainly, it appears that measurement of antibodies to CRP and possibly 
antibodies to C lq, may prove a tool for diagnosing inflammatory disease.
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T able 1.1.1 Components o f  the complement pathw ay
Name Function
Mannose-binding protein 
(MBP)
Binds to bacterial polysaccharides, activates MASP
MBP-associated protein 
(MASP)
Activates C4 and C2
Clq Binds to Ig in antibody-antigen complexes, activates C lr
C lr Activates C ls
Cls Removes C4a fragment and thus activates C4 ; removes C2a 
and thus activates C2
C4 Combines with C2
C2 Cleaves C3 and C5
C3 Combines with C5
Factor B Combines with C3(H20) ; cleaves C3 and C5
Factor D Activates factor B when B is in complex with C3b or 
C3(H20)
C5 Anchoring molecule for C6
C6 Anchoring molecule for C7
C l Anchoring molecule for C8
C8 Anchoring molecule for C9
C9 Forms pores in the membrane
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Table 1.2.8 Occurrence o f  IgG antibodies to Clq in autoimmune and renal diseases*
Disease Occurrence of Clq (%)
HUVS 100
MPGN 88
Lupus nephritis 83
SLE 34
Rheumatoid vasculitis 32
Sjogrens syndrome 13
RA 4
*Data adapted from (35,38,40,46,62,63)
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Table 3.1.2 Determination o f  cross-reactivity with C lq by anti-collagen antibodies in arbitrary 
units/ml
Antibodies to Clq
Immunoglobulin
type
Anti-GBM 
positive 1
Anti-GBM 
positive 2
Antibodies to Clq  
positive control
Antibodies to Clq  
negative control
IgG 27 0 1500 0
IgA 0 0 62 8
IgM 0 1 .. 148 40
Table 3.1.3.1 Antibody titres to C lq in normal healthy donors in arbitrary units/ml
No. IsG IgA IgM
1 50 13 52
2 50 13 54
3 57 13 32
4 50 45 35
5 70 13 46
6 188 ■ , 19 31
7 45 13 77
8 35 13 45
9 105 13 19
10 115 13 28
11 51 13 17
12 180 13 106
13 85 13 37
14 105 17 41
15 57 138 60
16 38 13 20
17 66 43 62
18 35 17 6
19 24 13 76
20 50 13 97
21 27 13 53
22 38 16 0
23 41 13 8
24 78 25 20
25 100 13 83
26 60 13 69
27 110 27 24
Mean + 2 SD 71+84 22+50 44+56
Upper limit 155 72 100
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Table 3.1.3.2 Comparison o f  antibody titres to C lq  in normal healthy donors and patients with 
inflammatory diseases. The figures are in medians and interquartile range. The asterisks depict the 
significance between normal human donors and patients.
IgG IgA IgM
Normal 57 13 41
(n=30) (41-100) (13-17) (20-62)
Inflammatory diseases 78 10 **
(n=64) (24-262) (4-20) (15-23)
SLE 139 * 9 18 **
(n=27) (32-386) (4-20) (16-26)
RA 34 g ** Y~j ***
(n=23) (0-190) (2-13) (15-20)
HAID 80.5 13 18
(n=14) (50-232) (7.5-27) (16-29)
p < 0 .0 5
p < 0 .01  
p <  0.001
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Table 3.1.3.3a Correlation o f  antibody titres to C lq in serum o f  inflammatory disease patients with
biological markers o f autoimmune disease activity (correlation coefficient r)
Variable IgG IgA IgM
Age n.s. n.s. n.s.
ANA n.s. n.s. n.s.
DNA Ab n.s. 0.56 ** n.s.
C3 n.s. n.s. n.s.
C4 n.s. n.s. n.s.
Cl inhibitor n.s. n.s. n.s.
Clq level n.s. n.s. n.s.
Table 3.1.3.3b Correlation o f  antibody tiP'es to Clq in semm o f  SLE patients with biological 
markers o f  autoimmune o f  disease activity (correlation coefficient r)
Variable IgG IgA IgM
Age -0.38 * n.s. n.s.
ANA n.s. 0.44 * n.s.
DNA Ab n.s. n.s. n.s.
C3 n.s. n.s. n.s.
C4 n.s. n.s. n.s.
Cl inhibitor n.s. n.s. n.s.
Clq level n.s. n.s. n.s.
* p < 0.05
** p < 0.01
*** p <0.001
n.s not significant
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Table 3.1.3.3c Correlation o f  antibody titres to C lq in serum ofRA patients with biological markers
o f  auto immune disease activity (correlation coefficient r)
Variable IgG IgA IgM
Age n.s. n.s. -0.46 *
ANA n.s. n.s. n.s.
C3 -0.50 * n.s. n.s.
C4 -0.46 * n.s. n.s.
Cl inhibitor n.s. n.s. n.s.
C lq level n.s. n.s. n.s.
Table 3.1.3.3.d Correlation o f antibody titres to C lq in serum of HAID patients with biological 
markers autoimmune o f disease activity (  correlation coefficient r)
Variable IgG IgA IgM
Age 0.67 n.s. n.s.
DNA Ab n.s. n.s. n.s.
C3 n.s. n.s. n.s.
C4 n.s. 0.78 *** n.s.
Cl inhibitor 0.78 *** 0.97 *** -0.64 *
C lq level n.s. n.s. n.s.
* p < 0.05
** p< 0 .01
*** p <0.001
n.s not significant
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Table 3.13.4a Correlation o f  biological markers o f autoimmune disease activity in patients with
inflammatory disease
Age ANA DNA C3 C4 Clinh
ANA n.s.
DNA -0.39 * n.s.
C3 n.s. n.s. -0.41 *
C4 n.s. n.s. n.s. 0.38 **
Clinh n.s. 0.30 * n.s. n.s. n.s.
Clq level n.s. n.s. n.s. n.s. n.s. n.s.
Table 3.1.3.4b Correlation o f  biological markers o f autoimmune disease activity in patients with SLE
Age ANA DNA C3 C4 Clinh
ANA n.s.
DNA n.s. n.s.
C3 n.s. n.s. n.s.
C4 n.s. n.s. n.s. 0.65 ***
Clinh n.s. n.s. 0.57 ** n.s. n.s.
Clq level n.s. n.s. 0.75 *** n.s. n.s. n.s.
Table 3.1.3.4c Correlation o f  biological markers o f autoimmune disease activity in patients with RA
Age C3 C4 Clinh
C3 n.s.
C4 n.s. 0.71 ***
Clinh n.s. 0.68 *** 0.64 ***
Clq level n.s. n.s. n.s. n.s.
Table 3.1.3 Ad Correlation o f  biological markers o f  autoimmune disease activity in patients with 
HAID
Age ANA C3 C4 Clinh
ANA n.s.
C3 n.s. n.s.
C4 n.s. n.s. n.s.
Clinh 0.59 * n.s. 0.999 *** 0.64 *
Clq level n.s. n.s. n.s. n.s. n.s.
* p <0.05
** p <0.01
*** p <  0.001
n.s not significant
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Table 3.1.3.5a Levels o f complement components in patients with various autoimmune inflammatory 
diseases (  median and interquartile range) and controls (normal range)
Normal range 
(n=30)
SLE
(n=27)
RA
(n=23)
HAID
(n=14)
C3 0.88-1.82 0.97 * ** 
(0.77-1.45)
1.31 **** 
(1.18-1.83)
0.21
(0.10-0.59)
C4 0.18-0.45 0.12 ; 
(0.08-0.22)'
0.18
(0.14-0.27)
0.14
(0.10-0.24)
Cl inhibitor 0.16-0.46 0.27
(0.20-0.33)
0.35 *** 
(0.24-0.39)
0.11
(0.10-0.26)
Clq level 63-158 63
(30-158)
63
(24-135)
143
(65-353)
Significant difference between * SLE and RA ; P<0.05, ** SLE and HAID ; P< 0.001, RA and 
HAID : P< 0.05, **** RA and HAID ; P< 0.001
Table 3.1.3.5b Proportion ofpatients with autoimmune inflammatory disease with lower than
normal complement component levels
SLE RA HAID
C3 10/23 (43%) 2/23 (9%) 12/14 (86%)
C4 17/24 (71%) 11/22 (50%) 9/14 (64%)
Cl inhibitor 2/22 (9%) 3/18(17% ) 2/3 (66%)
Clq level 13/27 (48%) 12/23 (52%) 3/14 (21%)
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Table 3.1.3.6 Comparison o f  antibody titres to C lq in serum samples ofpatients with incr-eased 
titres o f  anti dsDNA antibodies and patients with normal anti DNA antibody titres. The figures are in 
medians and interquartile range.
Increased anti dsDNA antibodies Normal anti dsDNA antibodies
IgG antibodies to C lq 206 * 58
(33-458) (3-139)
IgA antibodies to Clq 12 8
(3.5-47) (4-19.5)
IgM antibodies to C lq 17 16.5
(15.5-22.5) (15-20.5)
* p < 0.05
95
Table 3.2.1 Antibody titres to CRP in normal healthy donors in arbitrary units/ml
No. IgG IgA IgM
1 23 8 3
2 34 11 13
3 33 6 10
4 38 17 11
5 32 10 0
6 23 20 0
7 19 9 20
8 23 3 21
9 16 22 19
10 9 11 4
11 . 17 10 4
12 17 3 8
13 22 11 0
14 36 6 18
15 29 27 7
16 48 19 7
17 58 22 10
18 60 20 3
19 7 25 36
20 60 16 0
21 24 1 0
22 0 0 0
23 5 0 9
24 0 15 0
25 0 11 0
26 0 2 0
27 35 26 7
28 0 1 0
29 0 7 0
30 21 12 4
mean +2 SD 23+36 12+14 7+17
upper limit 59 28 24
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Table 3.2.2 Comparison o f  serum antibody titres to CRP (medians and interquartile range) in normal 
healthy donors and patients with inflammatory diseases. The asterisks depict the significance between 
normal human donors and patients.
IgG IgA IgM
Normal 22.5 11 4
(n=30) (6.5-34) (5-19) (0-10)
Inflammatory diseases 50 * * * 25.5 *** 8 *
(n=64) (31-75) (11-45) (4-19)
SLE 54  * * * 52  * * * 8 *
(n=27) (41-82) (14-50) (5-19)
RA 32 * 22* 6 *
(n=24) (25-55) (6-41) (1-17)
HAID 59 * * 22  * 9
(n=14) (29-93.5) (10-48) (5-17)
* p < 0 .0 5
** p < 0.01
*** p <0.001
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Table 3.2.3a Correlation o f antibody titres to CRP in serum o f inflammatory disease patients with levels
o f variables o f disease activity (correlation coefficient r)
Variable IgG IgA IgM
Age ■ -0.383 * n.s. n.s.
ANA n.s. n.s. n.s.
DNA n.s. n.s. 0.47 **
C3 -0.29 * n.s. n.s.
C4 -0.36 ** n.s. n.s.
Cl inhibitor n.s. -0.32 * n.s.
Clq level n.s. n.s. n.s.
Table 3.2.3b Correlation o f  antibody titres to CRP in serum o f  SLE patients with levels o f variables o f  
disease activity (correlation coefficient r)
Variable IgG IgA IgM
Age n.s. n.s. n.s.
ANA n.s. n.s. 0.40 *
DNA n.s. 0.46 * 0.56 **
C3 n.s. -0.43 * n.s.
C4 n.s. -0.39 * n.s.
Cl inhibitor n.s. n.s. n.s.
Clq level n.s. n.s. n.s.
* p < 0.05
** p < 0 .01
n.s not significant
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Table 3.2.3c Correlation o f  antibody titres to GRP in serum o f RA patients with levels o f  variables o f
disease activity (correlation coefficient r)
Variable IgG IgA IgM
Age n.s. n.s. n.s.
ANA n.s. n.s. n.s.
C3 n.s. n.s. n.s.
C4 n.s. n.s. n.s.
Cl inhibitor n.s. n.s. n.s.
Clq level n.s. n.s. n.s.
Table 3.2.3 .d Correlation o f  antibody titres to CRF in serum o f HAID patients with levels o f  variables 
of disease activity (correlation coefficient r)
Variable IgG IgA IgM
Age n.s. n.s. -0.55 *
DNA Ab n.s. n.s. n.s.
C3 -0.54 * n.s. n.s.
C4 n.s. n.s. n.s.
Cl inhibitor -0.82 *** -0.85 *** n.s.
Clq level n.s. n.s. n.s.
* p < 0 .0 5
** p < 0 .01
*** p <  0.001
n.s not significant
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Table 3.3.2 Comparison o f  C3d ELISA levels in the plasma o f normal healthy donors and patients
Disease Category Median
(Interquartile range)
Normal (n=l 1)
Inflammatory disease (n=45) 
SLE(n=15)
Renal (n=15)
HAID (n=15)
13 (2-23)
23 (17-30) *
23 (17-31) *
24 (21-30) * 
22 (16-27) *
* p<0 . 05
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Classical Pathway
Antigen-antibody complexes Ceil Surface Carbohydrate
C1qrs ► C4 4 MBP-MASP
► C4b —► C4a+C2a
C4bC2b
C3bC4bC2b
C5b
C6+C7+C8+C9
Alternate Pathway
CSbBbP► C3 4
C3bBbP
> C5a
C5bC6C7C8C9n (MAC)
Figure 1.1.2 The complement pathway.
MBP is mannose-binding protein and MASP is MBP-associated serine protease. P, 
B and D are properdin, factor B and factor D respectively. MAC is membrane attack 
complex.
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(a) (b) Globular Heads
- S -
CoUagen -like Stalks 
Triple Helices
3 Structural 
units
C1q
Figure 1.2.1 The structure of complement component C1 q
(a) Interchain and intrachain disulphide bonding in two collagen-like stalks, each 
formed by three peptide chains, A, B and C.
(b)A doublet of chains showing globular heads attached to the collagen-like stalks 
containing triple helices.
(c) A whole C1q molecule, which consists of six globular heads attached to six 
collagen-like stalks.
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antibodyantibody
antigen
antigen
Figure 1.2.4 Interaction of C1 q with IgG
The C1q component bridges two membrane bound IgG molecules. The antibodies 
interact via their Fc regions with binding sites on the globular heads of the C1q 
component
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Figure 1.3 Structure of C-reactive protein.
The GRP molecule consists of five identical, non-covalently bound subunits. Each
subunit is 187 amino acid residues long.
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C1q antiserum 1:1 anti- human serum 1:1
a’nti-human 
serum 1:1
Purified
C lq C lq  antiserum 1:4
C lq  antiserum 1:1 C lq  antiserum 1:2
Figure 3.1:1.1 Double-diffusion technique to determine evidence and quality of purified C1q. 
Precipitins were formed between the purified C1q and the C1q antiserum at all the 
dilutions, the strongest at 1:1, the next strongest at 1:2, and the weakest at 1:4.
No precipitins were formed between the purified C lq and the anti-human serum.
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...... ............
wc^wfttwaa.
PF C lq  C3 C4 k 1
Key ; PF protein fixation 
C lq antiserum to C lq
C3 antiserum to C3
C4 antiserum to C4
k antiserum to kappa
1 antiserum to lambda
Figure 3.1.1.2 Serum Protein Electrophoresis method to determine the quality of 
purified Clq.
The electrophoresis gel shows a single protein band in the protein- 
fixed migration. Protein analysis by immunofixation with C lq  
antiserum and C3, C4, kappa and lambda antisera identified this band 
as Clq. Immunofixation with C3,C4, kappa and lambda showed no 
discernible bands.
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5 0
l 4 0
c/3f " *
§  30 
<  
20
• e
LU
10
0 “ I
□DRIE^units/ml)
25
Correlation coefficient ; 0.354 (p<0.05)
Figure 3.3.1 Graph showing correlation of C3d DDRJE with C3d ELISA. The units 
are arbitrary and are defined differently in the two assays and should 
not be directly compared.
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